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SUMMARY 
Biomanufacturing for advanced therapies depends on the reliable and reproducible 
growth of cells. In some cases, the cells produce biomolecules that are the value-added 
product, while in other workflows the cells themselves are the final product. These cells, 
whether they are in vitro or in vivo, secrete biomolecules continuously. These secreted 
factors may have anti-inflammatory effects, signal neighboring cells for differentiation, or 
they may even be designer proteins with therapeutic potential that cells are engineered to 
produce. In most biomanufacturing workflows these secreted metabolites, exosomes, 
proteins, and other biological factors can also serve as the critical quality attributes (CQAs) 
that indicate current process state and final product quality. Researchers and industry 
professionals utilize a suite of sensor technologies to characterize the CQAs, but generally 
these analysis techniques suffer from a lack generality and granularity in the information 
they provide. Common approaches are i) unable to provide high resolution transient data 
for feedback input, ii) targeted, and therefore incapable of discovering which quality 
attributes serve as CQAs, and/or iii) bulk sensors that average otherwise potentially highly 
heterogeneous data.  
The Dynamic Sampling Platform (DSP) is a technology for real-time analysis of 
the chemical content of bioreactors. It synergistically combines aseptic, spatially resolved, 
direct-from-reactor sampling with inline sample treatment and rapid electrospray 
ionization mass spectrometry (ESI-MS) sensing to fill the void of existing process 
analytical technologies for real-time biomarker monitoring in biomanufacturing. DSP 
samples non-invasively from near where cells are growing to capture the rich 
microenvironment, with high relative concentrations of biomarkers, and subsequently 
 xx 
treats these samples for real-time electrospray ionization mass spectrometry (ESI-MS) 
analysis. ESI-MS is a powerful analytical technology for the detection of biomolecules, 
but it is hindered by a need for extensive sample treatment which has made the technique 
largely an offline approach. The DSP utilizes a novel “active sample treatment” to prepare 
complex biochemical samples for ESI-MS by conditioning the sample via selective salt 
removal, MS enhancing chemical infusion, and CQA biomolecule retention. The DSP is 
produced by employing advanced microfabrication techniques that allow for scalable and 
reproducible production of the device. The final device utilizes a micro-mass exchanger 
which replaces time consuming sample preparation steps with a ~1 second flow through 
reactor.  
This thesis outlines the design and system level integration of DSP for advanced 
biomanufacturing workflows. The batch microfabricated mass exchanger is combined with 
the dynamic sampling interface (DSI), a fluidic handling system for spatially resolved 
sample uptake, and an ion transfer interface for transmitting analytes from the DSP system 
to the mass spectrometer. The result is an analysis system with drop-in readiness for 
incorporation to existing pharmaceutical grade workflows in good manufacturing practice 
(GMP) facilities. Important results include the demonstration of active sample conditioning 
for enhanced ESI-MS performance, such as improved limit of detection, multi-component 
detection, and high molecular weight protein characterization in real-time. When applied 
to living cell cultures, DSP reveals that localized sampling is critical to enable detection of 
the cell status, i.e., cells in their proliferative, confluent, and differentiated state. Offline 
HPLC ESI-MS is correlated with real-time DSP analysis to demonstrate DSP’s value as 
both a  process analytical technology for bioreactor monitoring and as a discovery tool for 
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identifying the potential target biomolecules serving as CQAs for predicting the cell state. 
Collectively, this thesis’ results demonstrate DSP’s utility to help unlock the potential of 
advanced therapeutic cell manufacturing by providing detailed biochemical information 
about the process for closed feedback control of bioreactors, allowing for nascent therapies 





CHAPTER 1.  
INTRODUCTION: STATE-OF-THE-ART, MOTIVATION,  
AND RESEARCH OVERVIEW 
1.1  Enabling Nascent Biomanufacturing Workflows 
In the last 20 years biomanufacturing has seen a drastic increase in the scale of 
therapeutic production, particularly in the monoclonal antibody (mAb) and biologics space. 
These molecules are inherently more complicated to manufacture than traditional small 
molecule drugs, like aspirin, because they are produced by living organisms, i.e., cells. The 
cells used for biologics generally have their genome edited, or the cells are “engineered”, 
so that they produce the specific protein(s) of interest. In 1998, a problem with the 
manufacturing process for the drug Enbrel, a recombinant protein produced by Chinese 
hamster ovary (CHO) cells which are edited with human DNA, led to a shortage of the 
“miracle drug” used for rheumatoid arthritis. At the time, the company responsible for 
producing the drug sent a letter to 82,000 patients citing issues with manufacturing-caused 
delays in production. By 2002 the shortage completely vanished. It was reported that there 
was an excess amount of capability for biologics production, and the averted crisis can be 
attributed to a huge expansion of manufacturing facilities.1 Yet, other nascent cellular-
based therapeutics have not seen the same growth trajectory despite having access to the 
same facilities that enabled the high volume of biologics production prevalent today. While 
in the biologics industry a medically potent protein produced by the cell is the final product, 
in the budding cell therapy space the entire cell is the final product, which is comprised of 
thousands of different biochemicals. This difference makes characterizing and ensuring the 
safety, efficacy, and potency of cellular therapies far more challenging.  
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Cellular therapies are transforming how life-threatening ailments are treated with 
the advent of therapeutic applications (e.g., cancer immunotherapies) to cure diseases; 
tissue engineered medical products are also used to restore, maintain, and replace damaged 
organs.2-5 The outlook for these techniques is exhilarating, with over 900 investigational 
new drug applications for cell and gene therapy products reported by the FDA as of January 
2020. Similar to biologics, these new treatment methodologies depend on the reliable 
growth of cells (e.g., stem cells) in vitro, but a severe lack of scalable cell manufacturing 
techniques currently limits these treatments’ accessibility. This restricted production 
pipeline also results in low yield manufacturing, which causes excessive product pricing 
for patients. 
Many cellular therapies do not have effective assays for product quality or 
therapeutic potency, which means that the Chemistry, Manufacturing, and Controls (CMC) 
standards are not reliable enough for these promising therapies make it through final FDA 
approval. For those therapeutics that have reached market, such as the CAR-T cell therapy 
for certain types of leukemia, a lack of feedback control hinders the scale up of production. 
With the exception of just a few FDA approvals, most advanced therapies fail to reach 
market because the biomanufacturing processes lack suitable real-time quality control 
methods capable of monitoring cell bioreactors, and this has resulted in large batch-to-
batch variability, with ad hoc approaches to cell manufacturing. The lack of process 
analytical tools for quality control is reported as the main bottleneck to mass-market entry, 
and contributes substantially to the high  patient costs ($0.5M-$2.0M per treatment) 
associated with the few regenerative medicine techniques approved by the FDA to-date.6 
1.2 Sensors for Biomanufacturing 
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 Standard approaches to characterizing bioreactors usually exhibit some 
combination of being off-line, destructive, and/or targeted. These are undesirable 
properties for analysis approaches when the goal is real-time monitoring to serve as an 
input to a feedback control for therapeutic cell manufacturing processes. As cell cultures 
mature and go through developmental stages, the biomolecules they secrete as signaling 
and paracrine factors can also serve as critical quality attributes (CQAs) for cell 
biochemical state and therapeutic potency.7-9 Detecting and identifying these CQAs in real-
time, and understanding in what manner they correlate with the cell growth trajectory and 
final product quality, are key first steps toward unlocking the potential of cellular therapies.  
The widely adopted methods for continuous monitoring of bioreactors, including 
pH measurement, temperature measurement, off-gas mass spectrometry (i.e., monitoring 
of volatile compounds produced by cells in culture via mass spectrometry), infrared and 
Raman spectroscopy, all noninvasively capture “bulk” properties of the bioreactor. These 
bulk values are based on integral averages over the entire content of the bioreactor, and 
have indirect correlation to cell state. Although these sensors provide temporally sensitive 
information, they are subpar in offering detailed information such as the secretome’s 
complete biochemical composition or the spatial heterogeneity within the bioreactor.10-13 
Some progress has been made in the implementation of non-invasive technologies that 
deliver multi-dimensional information about the cell population in a bioreactor. For 
instance, advanced image processing to track and monitor cell count and distribution on 
microcarriers in a bioreactor14 or two-photon microscopy using endogenous fluorophores 
for monitoring stem cell differentiation15 provide important insight to the culture status in 
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terms of cell count and cell differentiation respectively, but do not provide insight to the 
CQA biomarkers that predict therapeutic potential, safety, or efficacy.  
As of yet, the level of quantitative detail required for high fidelity detection of 
CQAs has only seemed obtainable via offline methods such as liquid chromatography mass 
spectrometry (LC-MS),9 microarrays,16 and enzymatic assays (e.g., ELISA),12, 17 which 
have been the main workhorses for the characterization of bioreactor processes and 
biomarker discovery. These approaches suffer from significant time delays and low 
throughput that limits their utility for online reactor monitoring. Due to a deficiency in 
temporal resolution, not only do these approaches miss the transient nature of cell growth, 
they also are not amenable to incorporation into an online feedback control loop that is key 
for scaling-up cell manufacturing. Although there have been some successful FDA 
approvals for cell-based therapies, such as the CAR-T immunotherapy, a lack in process 
control at each manufacturing step (including the viral vector production, which is also 
produced via cell-based manufacturing) has contributed to high rates of batch failure that 
contribute to the exorbitant costs and lack of availability associated with these promising 
treatments.18  
Another shortcoming of nearly all current approaches to bioreactor monitoring is 
that they are limited to monitoring changes in the bulk media. The cell secretome is highly 
dynamic in nature, dependent on biological context, and spatially variant. As depicted in 
Figure 1.1, the region directly adjacent to the cell membrane has a rich biochemical 
environment whereas the region far from the cells has diluted concentrations of secreted 
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factors and instead is dominated by media components. Furthermore, the local chemical 
composition can reflect cell heterogeneity, while bulk media loses spatial specificity. 
Therefore, extraction of large samples that contain secretions from many cells inherently 
sacrifices potential CQA enrichment as well as key information on local changes that could 
be important indicators of cell product state. An effective quality control measurement 
technique should not only be real-time but should also enable localized sampling within 
Figure 1.1: While cell cultures mature, secreted biomolecules are in highest 
abundance near the cells’ surface. Traditional analysis techniques analyze bulk 
media, which includes temporally averaged biomolecular content and higher 
relative concentrations of molecules contained in stock media (e.g., fetal bovine 
serum (FBS), salts) that can mask the signature of quality indicating analytes. 
Rapid, small volume, localized sampling is an advantageous approach because it 
enables spatial and temporal probing of the cell culture, detecting the molecules 
when and where they are secreted. 
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the cell bioreactor: it should sample in close proximity to the cells to capture both spatial 
and temporal variations within a cell bioreactor.  
The benefit of localized sampling is illustrated in Figure 1.2. The left trace 
represents the time history of species near the cell membrane. The relative concentration 
of secreted biomarkers, which are the CQAs for cell manufacturing, may vary substantially 
with time. On the other hand a time history of the bulk, shown in the right graph in Figure 
1.2, indicates that high concentration additive biomolecules found in media (e.g. serum) 
are orders of magnitude higher in concentration when compared to the quality attribute 
biomarkers. While some CQAs may follow similar trends in both environments, such as 
“CQA 1” in Figure 1.2, localized sample is advantageous because it captures the cell 
Figure 1.2: Representative time histories of relative species concentration near 
(left) and far (right) from the cell membrane.  Sampling near the cell membrane 
captures the temporal variation of secreted CQA biomarkers, which are in high 
relative concentration near the cell. Traditional techniques capture time averaged 
signals from the bulk that are dominated by media additives that do not correlate 
with cell state.  
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microenvironment, which is comprised of low concentration biomarkers that are directly 
correlated with cell state. Lastly, by capturing quality attributes at their source the time 
delay between CQA secretion and detection is minimized, which is requisite for any sensor 
providing input to a feedback loop in biomanufacturing.   
1.3 Mass Spectrometry for Biochemical Sensing 
1.3.1 Electrospray Ionization Mass Spectrometry (ESI-MS) 
Mass spectrometry (MS) is an analytical tool that measures the mass-to-charge ratio 
of ions. In the biological sciences MS has widespread utility for characterizing 
biomolecules ranging from small metabolites to entire monoclonal antibodies. The 
ionization source for a mass spectrometer varies depending on application. In the early 
applications of MS, electron impact ionization was used to break covalent bonds and 
produce fragment ions. However, this fragmentation made it nearly impossible to analyze 
large, complex biomolecules. As MS developed as an analytical tool, new approaches 
emerged that “softly” ionized molecules including electrospray ionization (ESI) and matrix 
assisted laser desorption/ionization (MALDI). Both approaches have driven the field of 
MS forward in a significant manner. MALDI has tremendous utility for analyzing non-
volatile species and has broad applicability in the biological sciences. MALDI is 
particularly well suited to imaging studies, such as defining the spatial distribution of 
specific compounds on tissues.19 The MALDI process generally produces ions that are 
singly or doubly charged. This is an important phenomenon because it enables the 
identification of molecular ions of proteins, lipids, and carbohydrates and drastically 
simplifies resulting spectra. However, this limited ionization capability also limits 
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MALDI’s utility for analyzing high molecular weight biomolecules because they are 
outside of the detectable m/z range on most MS systems. On the other hand, ESI produces 
ions with multiple charge states and, theoretically, has an unlimited mass range.20 For this 
reason, ESI is far more effective at analyzing large molecules such as proteins that must be 
highly charged for MS detection. Additionally, ESI preserves non-covalent bonds and 
leaves molecules in a preserved state from the condensed phase to the gas phase, unlike 
MALDI which suspends analytes in a crystalline solid prior to ionization.21 
Electrospray ionization mass-spectrometry (ESI-MS) is an excellent approach for 
biochemical analysis due to its broad molecular weight coverage and capacity for unlabeled 
biomolecule detection and discovery. ESI-MS maintains the state of large biomolecules, 
requires no a priori labeling of biomolecules, and is very sensitive to low concentrations 
of chemicals (limits of detection in the nanomolar to even picomolar range).22 However, 
direct online ESI-MS of biologically complex samples (e.g., cell media) requires extensive 
sample preparation prior to the ESI process.23 One of the most important challenges in the 
MS field is the detection of ultra-low concentration species. The dynamic range of 
biomolecules in cell media can range from a few picograms per milliliter to milligrams per 
milliliter, making it difficult to impossible to detect under-represented proteins.24 
Traditionally, separation techniques such as liquid chromatography (LC) or capillary 
electrophoresis (CE) are employed when a large number of biomolecules are present in the 
sample. For example, when analyzing cell culture media, salt must be first removed due to 
the deleterious effect it has on ESI-MS, and then the biomolecules are separated via LC or 
CE before MS. This sample preparation reduces chemical noise, simplifies ESI charge 
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states, mitigates spectral feature overlap from different species, and ultimately enables 
high-throughput and automated biomolecule identification.21  
1.3.2 Sample Preparation Requirements for Online ESI-MS Analysis 
Although chromatographic methods are widely used to facilitate modern ESI-MS 
workflows for biochemical analysis, they are not required for ESI-MS analysis. At a 
minimum, chemicals that are not compatible with ESI-MS must be removed prior to 
analysis because they interfere with the ionization of biochemicals of interest. Chemicals 
widely found in lab spaces such as polyethlyeneglycol (PEG, commonly found in 
detergents), keratin (skin/hair, dust), and some polymers found in labware or commonplace 
solvents interfere with ESI-MS. In cell biological applications the most common source of 
interference are inorganic compounds (e.g., NaCl, KCl, etc.) that are not only ubiquitous, 
but present in far higher concentrations than biomolecules of interest. 
Figure 1.3: Illustration of electrospray ionization (ESI) operating in 
positive mode.  
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Figure 1.3 shows the positive mode ESI process, which produces ions with excess 
protons that are subsequently analyzed by MS detectors (not shown). Although some 
workflows utilize a negative electric potential on the spray to produce negatively charged 
ions, positive ESI was the version explored in the work presented here. Positive mode ESI 
is the most applicable to proteomic workflows (like those that target secreted CQA 
biomarkers) because negative ions are generally more difficult to analyse using advanced 
MS techniques like tandem mass spectrometry.25 During the ESI process, three major steps 
are involved in bringing analyte molecules from their aqueous state to gas-phase ions that 
are detected by the mass spectrometer: 1) a strong electric field is applied between the 
aqueous phase within the ESI source and a counter electrode, causing the production of 
charged droplets ejected from the Taylor Cone; 2) the charged droplets shrink due to 
repeated solvent evaporation and Coulombic fission; and, 3) multiply charged ions 
comprised of the analyte and cations such as H+, K+, Na+, are produced.26, 27  
For positive-mode ESI-MS workflows, producing “protonated” ions that are charged 
with only H+ ions is desirable. When multiple cations are present within the aqueous phase, 
the ESI process produces both “adducts” and “clusters”. Salt adducts are formed when a 
cation such as Na+ replaces H+ during ionization, while clusters are formed when an entire 
neutral molecule, like NaCl or water (incomplete desolvation), attaches to the analyte 
during the ESI process. Figure 1.4 illustrates an ion in the +5 charge state in the protonated, 
adducted, and clustered format. Note that many combinations of adducts, clusters, and 
protonated ions are produced at each charge state during the ESI process, which causes 
significant suppression of the protonated state associated with target analytes that is most 
suitable for unambiguous spectral speciation.  
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In order to demonstrate the effect inorganic salts have on biomolecule signal 
suppression, direct ESI-MS analysis of a model protein, cytochrome c (Cyt c, M=12,358 
Da), at 5 μM concentration with varying concentrations of inorganic salt KCl (0 to 9,900 
μM) was carried out. As shown in Figure 1.5, with no KCl present, a clear signal associated 
with Cyt c is detected. Charge states ranging from +8 (8 protons with a single Cyt c 
Figure 1.4: Example of +5 charge state of an analyte with mass “M” produced in 
positive mode ESI. The presence of salt ions (Na+) results in both adducts and 
clusters that suppress protonated species. With sample treatment, these salt ions 
are removed prior to the ESI process, enabling the production of protonated 
molecules for improved MS identification. 
 12 
molecule) to +19 are highlighted. By increasing the KCl concentration to 250 μM, an 
adduct peak is detected with a value of ~1550 m/z, indicative of a +8 charge state with 7 
H+ ions and 1 K+ ion. As the concentration of KCl is increased to 9,900 μM, complete 
Figure 1.5: ESI-MS analysis of cytochrome c (Cyt c) at the 5 μM level with varying 
KCl concentrations. Without salt, multiple charge states of the protonated Cyt c are 
visible. The addition of even moderate amounts of KCl produces parasitic adducts, 
which can be observed at the 250 μM KCl level. Complete Cyt c signal suppression is 
observed at the 9100 μM KCl concentration.  
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suppression of Cyt c is observed. In this experiment identifying the biomolecule is still 
possible because Cyt c was targeted for analysis. However, in untargeted approaches, not 
knowing the molecular weight of the target analyte beforehand makes extracting molecular 
identify challenging. Moreover, in biologically relevant solutions such as cell culture 
media, the levels of inorganic salts are usually in the ~100 mM range and in many cases 
more than one type of salt are present simultaneously.28-30  
The minimum sample treatment requirements for ESI-MS in biomanufacturing 
workflows can be estimated based on the data presented in Figure 1.5. The signature 
associated with Cyt c is visible up to the 990 μM level, but the presence of adducts and 
clusters suppresses the protein’s spectral signature above this level. In biomanufacturing 
applications where cell culture media is to be analyzed, the starting concentration for salts 
will be at least 100 mM, and therefore at least 99% of the salt must be removed for ESI-
MS detection of a single CQA biomolecule. For these experiments, Cyt c was the only 
biomolecule in solution at the 5 μM level, and only a single species of salt was present 
(KCl). In cell culture media, the presence of multiple salts and numerous biomolecules 
introduces the potential for increasingly complex adduct and cluster signatures that further 
convolute resulting spectra. Importantly, the concentration of CQA biomolecules may be 
significantly lower than the micromolar level, often in the nano, pico, and even attomolar 
range, which would necessitate even higher levels of selective salt removal to detect these 
low concentration biomolecules. Therefore, at a minimum, over 99% of salts should be 
removed from culture media prior to direct ESI-MS analysis, but for label-free monitoring 
of multiple secreted CQA biomarkers, the sample treatment requirements are likely to be 
even more stringent. An effective sample treatment approach should selectively remove 
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nearly all salt content while retaining CQA biomarkers to enable real-time ESI-MS 
analysis.   
1.4 Prior Real-time ESI-MS Applications  
Prior work towards inline sample preparation for ESI-MS applications involved 
devices with highly variable performance that were hand assembled, low throughput, or 
without inline ESI-MS analysis. Xiang et al. demonstrated inline dual-dialysis which 
included high and low molecular weight cut off membranes to isolate target biomolecules 
within a specific molecular weight range while also removing interfering salts.31 Although 
this device demonstrated the ability to successfully remove enough salt for applications to 
biologically relevant solutions, the large dead volume resulted in poor time resolution of 
the analysis (~20 min processing time) and large sample size.29, 32 Additionally, the hand 
assembled device is not well suited to practical applications where production scale-up 
would be desirable.  
Continuous flow, passive sampling from a pressurized bioreactor with spatially 
resolved biochemical detection has been demonstrated by Olivero et al. for a 3-D glial cell 
culture system using a device with inline microdialysis to desalt the sample for direct ESI-
MS analysis.33 The inline salt removal device, which also required hand assembly and used 
a cellulose dialysis membrane with high mass transfer resistance, enabled detection of 
moderate concentrations of soluble proteins with a time response of ~1 min. Tibavinsky et 
al.34 reduced online sample treatment time down to ~1 s with miniaturization via 
microfabrication of a mass exchanger with a monolithic ultra-thin nanoporous alumina 
separation interface for microdialysis.  
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The device created by Tibavinsky et al. was the inspiration for the work presented here 
on the Dynamic Sampling Platform (DSP), with significant advances to the fundamental 
desalination technology. In DSP, a microfabricated mass exchanger is integrated with an 
aseptic, spatially resolved sampling inlet and an inline ESI emitter, yielding a monolithic 
device capable of rapid biomolecule identification to meet the needs of online bioreactor 
monitoring. Additionally, exploration of new operating modes with an active introduction 
of MS signal enhancing chemicals, in addition to sample desalting, is implemented to 
enable detection of a broader range of biomolecules.  
1.5 The Dynamic Sampling Platform (DSP)  
Figure 1.6: The Dynamic Sampling Platform (DSP) incorporates three key 
elements: 1) spatially resolved, aseptic sampling interface, 2) mass exchanger for 
inline, rapid sample treatment and, 3) output for real-time analysis. As a platform 
technology, DSP can be optimized for any analytical output, but is optimized for 
ESI-MS in this work to enable DSP as both a quality monitoring (targeted) and  
discovery (untargeted) tool for identifying which quality attributes serve as CQAs. 
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The Dynamic Sampling Platform (DSP, Figure 1.6) is a technology for real-time 
chemical analysis comprised of three key components: 1) a spatially resolved sampling 
probe for aqueous sample uptake 2) a batch microfabricated mass exchanger for rapid, 
inline sample conditioning including removal of chemicals that interfere with analysis (e.g. 
salts for MS), exchange of enhancing solvents (e.g., “supercharging” molecules and 
organic acids for MS), and retention of larger analytes and, 3) an outlet for real-time 
analysis (e.g., ESI emitter). As a platform technology, DSP is fundamentally compatible 
with most applications where aqueous samples are to be analyzed. Further, DSP is designed 
to be compatible with a range of analysis techniques. For each analysis technique the 
requirements for sample treatment will be different, but the flexible DSP fabrication 
process can be easily modified for incorporation with other techniques such as Fourier 
transform infrared spectroscopy (FTIR) or nuclear magnetic resonance 
spectroscopy (NMR). For the work presented here, DSP was optimized for ESI-MS 
because this analysis method is appropriate for both quality monitoring and CQA discovery 
applications in biomanufacturing.  
1.6 Research Objectives 
The objectives of this research were chosen to establish DSP as a key part of the 
existing suite of sensor technologies in biomanufacturing. In addition to optimizing DSP 
for drop-in integration within new and existing workflows, the scientific goals of the work 
were tailored to enhance fundamental scientific understanding: 
1. Design of a robust micro/nanofabrication process for DSP, along with a fluidic 
interface package for facile integration with mass spectrometers. The result is an 
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integrated technology for aqueous sample introduction and inline sample 
preparation for continuous and online ESI-MS of complex mixtures. 
2. Development of an optimized DSP mass exchanger based on first-principle analysis 
of coupled fluid dynamics and mass transfer. Simulation guided design 
optimization with experimental confirmation of the optimized DSP for improved 
performance, including fast response time, efficient salt removal, and enhanced 
sensitivity of ESI-MS analysis of biomolecules. 
3. Exploration of the effect conditioning agents have on ESI-MS analysis of i) low 
concentration biomarkers, ii) multi-component systems, and iii) high molecular 
weight proteins. 
4. Development of a microfluidic sampling interface for localized sample uptake 
directly from cell bioreactors that matches biological timescales; integration of DSP 
with clinically relevant workflows where cell culture and analysis take place in 
different locations. 
5. Demonstration of the localized sampling from a cell culture in combination with 
DSP-ESI-MS analysis to capture the CQA biomarkers that allow the secretome-
based identification of the cell state (e.g., differentiated, proliferative, confluent) 
during a complete cell development cycle.  
6. Exploration of DSP as a discovery tool for identifying biomarkers in a cell growth 
bioreactor to establish the DSP utility as a biological discovery tool aiming at 




1.7 Thesis Organization and Overview 
The presented work is divided into three chapters covering the DSP technology 
development and relevant applications of the prototype systems, followed by concluding 
remarks and recommendations for future work. Chapter 2 is comprised of a detailed 
description of the DSP system design. First, the design requirements for any sensing system 
operating within biomanufacturing are outlined. The DSP solution is comprised of a 
sampling interface, a microfabricated mass exchanger, and an ion transport interface. The 
Dynamic Sampling Interface (DSI) is the engineered solution presented for providing 
localized, aseptic samples from directly within bioreactors. The microfabricated mass 
exchanger is central to DSP, not only treating samples in real-time, but also integrating the 
DSI and an ESI-MS outlet for inline analysis. An overview of the microfabrication process 
is given in this chapter, along with salient features which enable DSP. For drop-in 
integration to clinically relevant workflows, an ion transfer interface is incorporated with 
the DSP and the features and limitations of the technology are explored. Finally, a 
computational-model guided approach to estimate the relevant mass-transport in the DSP 
mass exchanger is employed. A simple change in the fluidic package is implemented to 
significantly improve device performance for treating chemically complex samples.  
 In Chapter 3 the integrated DSP system is applied to proxy cell culture solutions 
comprised of soluble biomolecules in high salt content solutions. With constant sample 
composition (5 μm Cyt c, 100 mM KCl) different types of active-conditioning and their 
effects on real-time ESI-MS are explored. Conditioners, including acetic acid, methanol, 
ammonium acetate, and, notably, super-charging molecule 3-nitrobenzyl alcohol (m-
NBA), are shown to improve the real-time ESI-MS detection of Cyt c. The effects of 
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supercharging molecules are further probed and shown to improve sensitivity to low 
concentration biomarkers and to enable multicomponent detection. Finally, the improved 
crossflow orientation DSP is utilized to facilitate high weight protein detection. The 
superior conditioner orientation, along with optimized conditioner composition, enables 
the detection of these difficult-to-detect monoclonal antibody fragments, which is an 
important application for the already established biologics industry.  
 DSP use for live cell analysis is presented in Chapter 4. The crossflow design, with 
integrated localized sampling capability, is applied first to three types of clinically relevant 
cell types (hMSC, HUVEC, NHLF) for fingerprinting. For this exploratory work localized 
sampling is shown to reveal a significantly different MS signature when compared the bulk 
media samples, demonstrating that the resulting ESI-MS analysis of a cell culture is highly 
dependent on where the sample is taken from. These results suggest that by sampling from 
near the cell membrane secreted molecules are captured for analysis that correlate with the 
cell state directly. These results also motivated the longitudinal study of a culture of 
MC3T3-E1 cells (murine preosteoblasts) throughout their entire cell cycle. Post hoc 
analysis using a principal component analysis (PCA) approach reveals that localized 
sampling is key to detecting cell state, including differentiation, proliferation, and 
confluence. Lastly, a workflow for applying DSP with complimentary approaches such as 
high performance liquid chromatography (HPLC) is presented.   
 In the final chapter, conclusions are presented and future work is outlined. One 
major area of interest is optimizing sample conditioning for high/low molecular weight 
cutoff applications. Filtering out high molecular weight proteins that are found in high 
abundance in cell media, such as albumin, is important for clinical applications because 
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these molecules dominate during MS analysis and mask the signal of lower concentration 
CQA biomolecules. In addition to filtering out high molecular weight species, retaining 
smaller biomolecules is also of interest. Optimizing the integrated nanoporous membrane 
for reduced pore size can help retain smaller biomolecules of interest. Potential cell therapy 
testbeds of immediate clinical relevance, such as interferon-gamma primed mesenchymal 




CHAPTER 2.  
DSP SYSTEM LEVEL INTEGRATION  
The DSP was developed for integration with cell bioreactor monitoring in compliance 
with Good Manufacturing Practice (GMP) standards. The rules and regulations associated 
with GMP necessitate that industrial grade biomanufacturing processes adhere to stringent 
operating conditions that govern the entire process, including the integration of process 
analytical technologies (PAT). The DSP as a PAT system was developed with a holistic 
design approach to create an integrated analytical approach supported by tools capable of 
sample uptake, treatment, transport, and analysis. It incorporates a sampling interface for 
aseptic, spatially resolved sample uptake from a bioreactor followed by an inline sample 
treatment protocol for chemical modification and subsequent real-time ESI-MS analysis. 
At the core of the DSP system is the batch microfabricated device which integrates clog 
resistant counterbores for the inlet and outlet capillaries with a ~20 nL micro-mass 
exchanger that contains the sample channel and the active conditioning region. The DSP 
fabrication process uses state-of-the-art MEMS foundry techniques that are highly 
repeatable and scalable to meet high volume demand in future biomanufacturing 
workflows. The fabrication was carried out in the shared-user facility at the Georgia Tech 
Institute for Electronics and Nanotechnology (GT IEN). While the microfabricated 
exchanger is central to the DSP system, the auxiliary systems allow for GMP drop-in 
integration capability. The fluidic interface package, dynamic sampling interface (DSI), 
and ion transfer interface are each critical technologies for enabling clinical workflows 
operating under GMP standards where the cell culture, analysis instrument (e.g., mass 
spectrometer), and DSP system may each be in spatially disparate locations. Design and 
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integration of all aspects of DSP result in a robust system for deployment into new and 
existing biomanufacturing workflows.  
2.1 Good Manufacturing Practice Integration  
The DSP approach to bioreactor monitoring was developed with the end-use 
application in mind. Therapeutics produced from biomanufacturing workflows, like 
biologics and advanced cellular therapies, must adhere to strict standards that govern their 
production. Good manufacturing practices (GMP) or current good manufacturing practices 
(cGMP) are a set of guidelines and operating principles set forth by governing bodies such 
as the FDA to ensure that the final therapeutic product is consistent, safe, and efficacious. 
GMP regulations span every aspect of the production including record keeping, cleanliness, 
sanitation, equipment verification, air purity, raw material quality, etc.35 Most GMP 
requirements are relatively open-ended, and therefore the approaches from each 
manufacturer to meet these standards differ. Between processes there is some consistency 
in that biomanufacturing processes related to cell culture take place in clean (e.g., low 
particle count, sterile) environments following strict protocols where contamination is 
unacceptable. Analysis of the cell culture, on the other hand, most often takes place in a 
separate location/lab with different standards for cleanliness and ambient conditions. Any 
biomanufacturing sensor system must be designed to remove the risk of introducing 
contamination to the culture while still providing valuable information on measured 
process parameters. For instance, sensors that measure pH, temperature, dissolved oxygen, 
or glucose usually are embedded into the bioreactor in a manner that prevents 
contamination.36 For assays that are not in situ, every step from sample uptake to sample 
analysis must be minimally invasive and completely compatible with GMP requirements.35  
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The GMP facility at the Georgia Tech’s Marcus Center for Therapeutic Cell 
Characterization and Manufacturing (MC3M) is a proxy for industrial environments. This 
facility was used as a test bed for the DSP prototype deployment. The layout for the MC3M 
GMP facility is shown in Figure 2.1. The areas relevant to the integration of DSP are 
highlighted in red, namely, the ISO 7 and test suite. The ISO 7 suite is a cleanroom 
environment. Within this area there is a biosafety hood and an incubator, and this is where 
Figure 2.1: The GMP facility at Georgia Tech’s MC3M Center serves as a proxy to 
industrial environments for cell therapy manufacturing. Importantly, low particle 
count (ISO 7) suites where the cells are cultured are separated from test suites 
where analysis occurs. For effective application of DSP, sample uptake, treatment, 
and transfer for analysis must occur in a manner that does not affect any of the 
GMP requirements. Image courtesy of FLAD Architecture. 
 24 
cells are cultured. Adjacent to the ISO 7 suite is the test suite, where an analysis instrument 
is kept. For the work presented here, a Thermo FisherTM Q-Exative Plus mass spectrometer 
is housed in the test suite. For any real-time coupling between the culture and the analysis 
system, a sample must be transported from the ISO 7 suite (where cells are cultured) to the 
analytical suite (where analysis takes place) without affecting the sterility of the cell culture 
or violating GMP protocols. For example, in the facility shown in Figure 2.1, an operator 
can only walk in one direction, from the ISO 7 suite to the analysis suite, because the higher 
ambient pressure in the ISO 7 suite reduces the chance of contaminants traveling from the 
analysis suite to the ISO 7 suite. The DSP system was designed for flexible integration into 
restrictive environments similar to the GMP facility at Georgia Tech to enable aseptic 
sampling, inline treatment, long distance sample transport, and real-time ESI-MS analysis. 
 The DSP sample treatment mass exchanger is central to the DSP technology. This 
device is fabricated using a robust microfabrication process that reduces batch-to-batch 
variability and provides precise control over feature size. The DSP mass exchanger has 
monolithic fluidic interconnects that are designed for facile integration with a sampling 
inlet and an ESI outlet. Restrictions on aqueous sample transport, i.e., sample dilution and 
mechanical pump limitations, motivated the integration of a small-dead volume sampling 
system and a long-distance ion transport interface to couple the DSP with an MS system 
for real-time analysis. The layout of the DSP analysis system for GMP integration is 
illustrated in Figure 2.2. The dynamic sampling interface (DSI) enables aseptic, spatially 
resolved sample uptake from a cell growth bioreactor. The microfabricated portion of DSP 
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integrates the sample interface with a mass exchanger and an ESI source, which treats 
complex cell culture media and produces ions for MS analysis inline. The ion transfer 
interface transports the analyte ions in gas phase from the ISO 7 suite to the MS for real-
time analysis.  
2.2 Dynamic Sampling Interface (DSI)  
Secreted biomolecules from cells growing within a bioreactor can be correlated to 
cell health, propagation, and differentiation.7, 8, 23, 37-39 As cells secrete, the released 
biomolecules rapidly become less concentrated as they diffuse away from the cell 
membrane. As a result, bulk sampling away from the cells will uptake the target 
biomolecules at significantly reduced concentrations. These bulk samples also capture a 
temporally averaged media composition, which makes time dependent monitoring 
impossible. Further, the presence of high abundance molecules such as albumin (contained 
in serum) commonly found in cell cultures provide an overwhelming background for ESI-
MS detection of low abundance secreted analytes. Therefore, spatially and temporally 
Figure 2.2: Layout of the constituent technology for the DSP analysis system, 
including the dynamic sampling interface (DSI) for sample uptake, the DSP mass 
exchanger/ion source for inline sample treatment and analyte ionization, and the gas 
phase ion transfer interface to the MS for real-time analysis.  
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resolved sampling is essential for high sensitivity monitoring of cell secretomes to enable 
1) the mitigation of spatial dilution and time averaging of secreted biomolecules by 
analyzing the secretome in the immediate vicinity of cells or cell carriers,  2) the capability 
for capturing the transient cell secretion events as online sample treatment by DSP affords 
a nearly real-time ESI-MS analysis, and, 3) the probing of spatial heterogeneity of 
secretomes within the bioreactor environment in correlation with the spatial distribution of 
2D and 3D cell cultures.   
Figure 2.3: The dynamic sampling interface (DSI) consists of 4 components: 1) a bi-
directional, variable flow rate pump with sample for uptake/infusion; 2) a 
switching valve or quick disconnect fitting for isolating sampling/infusion steps; 3) 
a sampling probe for localized secretome intake; and, 4) interconnecting tubing for 
sample transport to DSP. Sample uptake can be carried out with dynamic pressure 
profiles tuned for rapid, low dilution sampling.  
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Figure 2.3 and Figure 2.4 depict the key components of the Dynamic Sampling 
Interface (DSI) for integration of DSP with a bioreactor. These include 1) a pump for bi-
directional sample uptake/infusion, e.g., syringe pump, 2) a switching valve or quick 
disconnect fitting for isolation of flow during uptake and infusion, 3) a flexible capillary 
terminated with a small size orifice to capture small volumes of the reactor content locally, 
i.e., near cells for probing the secretomes, and, 4) capillary connection to DSP for online 
ESI-MS analysis. During sample uptake, the flow rate can be tuned to match the rate and 
duration of the chemical secretion of the cells, thus capturing transient events in the reactor. 
On the other hand, during infusion, the flow rate should be tuned for matching the optimal 
flow rate required by DSP for desalting, active sample conditioning, and subsequent ESI-
Figure 2.4: The dynamic sampling interface (DSI) separates sample uptake from 
sample infusion.  During infusion, constant flow rate matches that necessary for 
consistent ESI-MS.  
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MS analysis. For a given ESI spray capillary size (i.e., emitter tip inner diameter), only a 
small range of flow rates will produce stable spray, and therefore the sampling interface 
should infuse to match this optimal range. In Figure 2.3, the difference in pressure between 
ports A and B illustrates that sample uptake can be dynamically changed to capture the 
secretion dynamics using small extracted liquid volumes, whereas during infusion (Figure 
2.4) the pumping pressure difference is constant for sustaining an optimal, steady flow rate 
during DSP infusion to ESI-MS.  
The sampling interface should be able to uptake volumes as small as necessary to 
capture the molecular release during the localized cell secretion event, which is expected 
to be in the few nanoliter range. However, the dead volume of the DSP mass exchanger 
(20 nL) is about 10X above this level. Therefore, the entire sampling interface and DSP 
dead volume was initially filled, or “primed”, with a non-interfering liquid prior to 
sampling from the bioreactor to enable only a small volume sample to be extracted without 
the introduction of air bubbles into the system. This is illustrated in a simplified diagram 
shown in Figure 2.5. 
 As a small sample is taken up into the system, a liquid “plug” will flow through the 
piping and valves of the primed sampling interface (Figure 2.3, Figure 2.4). As the liquids 
are assumed to be miscible, dispersion of the sampled liquid plug will dilute the sample as 
it advances through the sampling interface and to the DSI outlet/inlet to DSP. According 
to Taylor’s dispersion theory,40, 41 lower flow rate and smaller capillary diameter will result 
in reduced dispersion effects. However, as velocity, transit time, and system dead volume 
are related to the dispersion phenomenon, the design requires careful optimization, 
balancing the reduction in the device response time with improved sensitivity that comes 
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with a less dispersed sample. Another consideration is that as flow rates become smaller, 
axial diffusion will become significant as the Peclet number approaches unity. Both 
extremes are illustrated in Figure 2.5. In this simplified representation of the sampling 
interface, a small plug of a homogenous sample (e.g., cell culture media) is assumed to 
have an initial concentration of Co as it enters a tube which is filled with a miscible liquid 
(e.g., water). Diffusion or dispersion will cause the initial plug to spread along the length 
of the tube, and the species are now diluted in a larger volume. The mean concentration, 
Cmean, can be estimated as an integral average of the total species over the new volume. 
The same amount chemicals that were present in the initial plug are now in a larger volume, 
hence Cmean is always less than Co.  In both cases, a lower mean concentration will affect 
Figure 2.5: During sample transfer, a small liquid plug is transmitted through 
the primed fluidic interface. The plug dilutes due to both diffusion and 
dispersion effects that reduce the average concentration of the sample. At one 
extreme, diffusion dominates the dilution while sample transmission time 
increases (Pe = 1). In the other extreme (Pe>>1), dispersion effects dilute the 
sample although sample transmission time is reduced. A reduced mean 
concentration, taken as the integral average of species over plug volume, will 
affect the ESI-MS detection of already low concentration species. 
 30 
detection of the sample, so a design criterion for the DSI is to preserve the initial plug 
concentration during transmission.  
 Figure 2.6 illustrates the effect that flow rate and capillary diameter have on the 
mean concentration of a liquid plug within a 25 cm long capillary. In the flow regime where 
DSP operates (10-50 μL/hr) the output concentration of a small plug is nearly linearly 
proportional to flow rate and independent of inner diameter. One solution is to minimize 
the inner diameter the capillaries as a smaller total volume will transmit samples faster. 
However, the pressure drop in a capillary scales inversely with tube diameter raised to the 
fourth power for a given volumetric flow of incompressible fluid, and therefore the tradeoff 
is high operating pressures. It was found that longer fluidic paths between the pump and 
Figure 2.6: Mean concentration versus flow rate for a 25 cm capillary 
(left) and effective diffusion coefficient (right) based on Taylor-Aris 
dispersion effects. 
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sampling inlet caused leaks and bubbles that interfered with both sample uptake and DSP 
operation during infusion. The optimal operating mode for DSI was to uptake enough 
volume to fill the entire sampling interface and to then infuse directly through DSP for 
immediate ESI. Two operating modes were found to function well: 1) drawing enough 
liquid through the inlet to fill past the switching valve, or, 2) replace the switching valve 
with a quick disconnect fitting and sampling directly from the culture before reattaching 
the sampling inlet to the quick disconnect fitting. In either case, minimizing sample fluidic 
transmission lengths reduced the effect of dispersion. This mode of operation was found to 
function well for prototype experiments where the mass spectrometer, sampling volume, 
and DSP system were in close proximity. For GMP integration (Figure 2.1) it is more 
appropriate to transfer dry ions from the DSP outlet to the MS inlet via an ion transfer 
interface instead of transferring the samples in their liquid state because of a significant 
separation length between the sampling point in the cell culture and analytical suite where 
MS analysis is performed.  
2.3 Ion Transfer Interface 
The ion transfer interface is a technology for transferring dry ions over a long 
distance (~1-8 meters) from their source to the mass spectrometer.42 Instead of ionizing 
directly in front of the mass spectrometer, a cascaded pressure glide system from 
atmospheric conditions at the ion source to the reduced pressure (vacuum) near the inlet to 
the mass spectrometer is established to transfer the ions over long distances. Figure 2.7 
demonstrates the operating principal of the ion transfer interface.42 A vacuum, generated 
by an auxiliary vacuum pump, is drawn on a customized MS vacuum box mounted on the 
front of the MS. The pressure within the vacuum box is higher (~102 Torr) than the pressure 
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generated by the MS internally (~10-6 Torr), which enables a multistage ion transfer 
between different evacuated zones. Ions are generated in ambient pressure at their source, 
in this case the DSP outlet, and transferred through a 3/8” OD, 5/16” ID TygonTM tube by 
the high flow rate vacuum applied the MS vacuum box. Once the ions reach the vacuum 
box at the intermediate pressure, the internal MS vacuum draws them into the instrument 
for analysis. 
 A prototype design was first developed for a Bruker MicrOTOF MS with a 1-meter 
transfer distance. A CAD model of the ion transfer interface for this geometry is shown in 
Figure 2.8. In this design, the MS inlet had to be modified to extend the inlet within the ion 
transfer tube for ions to be detected. The vacuum drawn by the Bruker was found to be too 
weak to overcome the vacuum of the bench-top pump used for ion transfer. Increasing the 
pressure within the vacuum box was found to be an inadequate solution because ions failed 
to reach MS the vacuum box with a smaller pressure differential between the ESI outlet 
and the MS vacuum box. For this reason, a custom MS inlet was designed to extend into 
Figure 2.7: The gas phase ion transfer interface uses a multistage vacuum system to 
transfer ions from their source (DSP) to the MS inlet. A vacuum drawn on the MS 
vacuum box drives ions from the ESI emitter to the MS inlet, while the vacuum 
inside the MS draws the ions from the MS vacuum box to the MS for analysis. 
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the ion transfer tube, which improved ion transfer efficiency. Other MS systems, like the 
Thermo Fisher system used to demonstrate GMP integration, were observed to have 
sufficient pressure drop from the MS vacuum box to the MS system such that no 
modifications to the MS inlet were necessary.  
To test ion transfer efficiency in the prototype system on the Bruker MS, 5 μm 
cytochrome c (Cyt c) with 1% AA was infused directly to the MS and then infused through 
the 1-meter ion transfer tube of the ion transfer interface. Figure 2.9 shows the comparison 
of the resulting spectra for the two methods, and in both cases a clear signal associated with 
Figure 2.8: Ion transfer interface design for the Bruker MicrOTOF 
MS. A vacuum generated by a bench-top vacuum pump draws ions 
from approximately 1 meter away to the modified MS inlet, which is 
extended ~5 mm into the ion transfer tube. 
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Cyt c is obtained. It has been reported that the trend for ion survival in the interface is 
dependent on ion size and charge state. Larger ions, with lower charge states, are observed 
to transfer more efficiently through the length of the interface because they have lower bulk 
diffusion coefficients and are affected by space charge repulsion to a lesser degree.42 In the 
MS spectra corresponding to ion transmission through the interface shown in Figure 2.9, 
lower charge states (i.e., +7 and +6 states, m/z ~1766 and ~2060 respectively) are present 
Figure 2.9: Comparison of direct infusion and ion transfer of 1% aa, 5 μM Cyt c. 
The higher intensity of lower charge states in the ion transfer spectra is likely due to 
enhanced droplet desolvation in the ion transfer interface, although it is reported 
that lower charge state ions transfer more efficiently.  
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in higher abundance, which may be due to the increased transfer of low charge state ions 
through the ion transfer, but can more likely be attributed to enhanced desolvation as none 
of the other charge states appear to change in relative intensity. The ion transfer design was 
not required for experiments with the Bruker MS, where direct ESI-MS was possible. The 
MS within the GMP facility (Figure 2.1), on the other hand, required the integration of the 
ion transfer interface to enable real-time ESI-MS of samples which could not be infused 
directly to the instrument.  
 The next iteration of the ion transfer interface was designed for a ThermoFisherTM 
Q-Exactive Plus mass spectrometer located in a GMP-level facility on GT campus (Figure 
2.1). The ion transfer interface was designed for ion transmission over a ~3.5 meter 
distance. This length was selected to transfer ions from the ISO-7 suite, where cells are 
cultured, to the mass spectrometer isolated in the analytical suite to meet GMP 
requirements. This facility serves as a proxy to pharmaceutical/clinical grade 
biomanufacturing, where it is expected that cell cultures in production lines will be separate 
from analytical suites. Therefore, demonstrating that the ion transfer interface is capable of 
transferring ions from a remote bioreactor to the MS is important for enabling drop-in 
integration of DSP into GMP workflows.  
 A CAD model of the ion transfer interface implemented in the GMP cell 
manufacturing facility is shown in Figure 2.10. The design was similar to the baseline used 
for the Bruker mass spectrometer, with a major change to the system support and a different 
vacuum pump for generating flow. The front-end design of the Thermo Fisher MS was 
reverse engineered to create an adjustable latching system that was used to tune the 
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clamping force between the MS front end and the vacuum box. This design reduced leaks 
at the MS/vacuum box interface, which ultimately resulted in better ion transfer efficiency 
and longer distance transport compared to the Bruker system, which was attached to the 
MS via elastic bands (i.e., rubber bands). Instead of a bench-top vacuum pump, a high flow 
rate ShopVacTM was used to generate flow from the ion source to the MS inlet. The 
ShopVac provided high flow rate suction with moderate pressure drops. In agreement with 
reported data, higher flow velocity within the ion transfer interface improved ion transfer 
efficiency. For this iteration of the ion transfer interface, no modifications to the MS inlet 
were required, and it was observed that ion transfer efficiency was unaffected by the 
relative position of the transfer tube and the MS inlet, unlike the Bruker design where it 
was critical that the customized MS inlet extended into the ion transfer tube. It is expected 
Figure 2.10: Thermofisher Q-Exactive Plus ion transfer interface 
CAD model. 
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that the Thermo MS is less sensitive to the relative positioning of the ion transfer tube exit 
for two reasons: i) the inlet orifice to the MS is larger and ii) the difference between the 
pressure in the interface box and the MS is greater because the ShopVac operated at 
relatively high pressure (~100 Torr). These factors increased the relative flow rate into the 
MS system and therefore more ions were drawn into the MS for analysis compared to the 
Bruker system. 
 To determine the impact of ion transfer on MS limit of detection, a comparison was 
performed using the commercial nanoESI source provided by ThermoFisher (direct ion 
infusion to the MS) and via the ion transfer interface.  Varying levels of Cyt c in a 50/50  
acetonitrile/H2O solution with 0.1% formic acid were used as the test samples. For direct 
infusion to the mass spectrometer with the commercial source, the limit of detection was 
found to be 15 nM Cyt c, while for the 3.5 meter long ion transfer interface it was 100 nM. 
Additionally, intensity dropped approximately 2 orders of magnitude, from 106 counts to 
104 counts as measured by the MS due to ion losses during the long distance transport. As 
reported in literature, only the lower charge states of Cyt c were observed in the ion transfer 
interface (+9 and lower) whereas in the direct infusion case a full range of charge states 
was detected. This confirms prior reports that the ion transfer interface preferentially 
transmits lower charge state ions, which may have implications for MS/MS which benefits 
from highly charged species.42 As the loss of some sensitivity as a result of ion transfer 
will impact CQA biomarker detection in cell culture, the ion transfer interface has been 
identified as an area requiring further improvement 
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2.4 DSP Mass Exchanger 
The DSP is designed for continuous flow sample treatment in a tangential flow mass 
exchanger. Figure 2.11 illustrates a cross section of the DSP mass exchanger. Sample flows 
through the sample channel at 10-50 μL/hr to match the appropriate flow rate of the ESI 
Figure 2.11: The DSP mass exchanger integrates a size selective membrane to 
separate a sample channel from a conditioner channel. Sample flows through the 
sample channel at 10-50 μL/hr, whereas the conditioner flow operates at 50 mL/hr. 
During sample treatment, species which interfere with ESI-MS analysis diffuse 
from the sample channel to the conditioner channel through the membrane. 
Simultaneously, chemical “conditioners” the enhance ESI-MS sensitivity to CQA 
biomarkers diffuse from the conditioner channel to the sample channel. Target 
CQA biomarkers are retained in the sample channel because their large size hinders 
diffusion through the membrane, resulting in a compatible sample for real-time 
ESI-MS analysis. 
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emitter for real-time MS analysis. Active conditioning flows at 50 mL/hr and is separated 
from the sample channel by a size selective Al2O3 membrane which fluidically couples the 
sample and conditioner channel. The nanoporous membrane allows small molecules, for 
example, salt ions that interfere with MS analysis and/or acids providing protons for 
ionization, to diffuse freely into or out of the sample. Larger molecules, such as target CQA 
biomolecules, diffuse through the membrane at a reduced rate because their transport 
through the nanopores is restricted in proportion to their molecular weight. Therefore, 
larger size biomolecules are preferentially retained in the sample channel during treatment, 
while the smaller salt molecules readily diffuse out to the salt-free conditioner channel 
driven by the concentration gradient. The monolithic mass exchanger enables DSP’s 
“active sample treatment” protocol, which refers to the simultaneous infusion of signal 
enhancing molecules from the conditioner channel to the sample channel, removal of small 
molecular weight interfering species (primarily salts) from the sample channel, and 
retention of large biomolecules in the sample channel. The pore size is 50 nm in the 
membrane, which retains most signaling and paracrine factors, but can lead to inadvertent 
removal of some smaller CQAs as explored in CHAPTER 3.34  
A representative CAD model of the DSP mass exchanger is shown in Figure 2.12. In 
this figure, the inlet and outlet are represented by 1.5 cm long, 360 μm OD cylinders for 
visualization purposes. In practice, the DSP inlet is 360 μm OD PEEK tubing with an 
extended length (5-20 cm) while the outlet is a fused silica ESI emitter. The conditioner 
channel is 4.5 mm wide and 11 mm long, defined in a 500 μm thick silicon wafer. 
Conditioning flow is introduced via a fluidic interface package (section 2.6) and flows 
along the bottom of the conditioner channel, tangentially to the size selective Al2O3 
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membrane. The sample channel is below this membrane. The DSP sample channel is 5 μm 
deep, 200 μm wide, and 2.2 cm long. The sides of the sample channel are defined by SU-
8 3005, the bottom is SiO2 on Si, and the top is Al2O3. The active portion of the sample 
channel, where treatment occurs, runs parallel to the length of the 11 mm long active 
Figure 2.12: A) A CAD model of the DSP illustrates the final mass exchanger 
geometry as well as the dimensions of the active conditioner channel and the 
section line used for visualization in C. B) The DSP conditioner channel is 
separated from the sample channel by a thin (<10 m) nanoporous Al2O3 
membrane which fluidically couples the two channels. An SU-8 layer defines the 
sample channel geometry (5 μm tall, 200 μm wide, 2.2 cm long) and a silicon base 
layer enables monolithic integration of 360 um OD tubing via through hole 
counterbore geometries. C) The section view from part A is used to visualize the 
sample channel cross section to scale.  
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conditioner channel. The inlet and outlet interfaces for the DSP mass exchanger are 
identical counterbores (inset image, Figure 2.13) for inserting the 360 μm OD capillaries 
for the sampling probe inlet and electrospray tip outlet. The counterbore design allow for 
precise alignment of the inner through channels within the capillaries with the ~60 μm 
through holes in the wafer for sample transfer in and out of mass exchanger, while 
mitigating potential clogging at the interconnection joints due to epoxy overflow, silicon 
chipping or fused silica tubing fracture. The total volume of the DSP mass exchanger, from 
inlet to outlet, is merely 22 nL, a very small value which is essential for minimizing the 
dead volume and in turn reducing the sample size and the transit time of the sample 
analysis.  
2.5 Microfabrication Overview 
The DSP microfabrication (detailed process information, lessons learned, and 
process parameters are described in APPENDIX A) incorporates aspects of prior work by 
Figure 2.13: Process A for microfabrication of the counterbore capillary recess. 
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Tibavinsky et al. but extends the processing capabilities and introduces new steps into a 
microfabrication process to produce a robust microfluidic mass exchanger for flexible 
integration to ESI-MS workflows.34, 43 The DSP microfabrication process is divided into 
three main stages: process A, B, and C (Figure 2.13, Figure 2.14, and Figure 2.15 
respectively). These processes were intentionally designed to place wet etching steps 
before the sample channel was enclosed during bonding (process C). Once bonded, only 
dry etching steps were carried out on the device stack. This significantly improved device 
reproducibility and reduced the chance of clogs in the final device.  
A novel feature of the DSP system is the clog resistant counterbore geometry (inset, 
Figure 2.13). This feature is used for precise alignment of the fluidic inlet/outlet and 
mitigates the risk of clogs caused by fractured silica from the ESI outlet or epoxy used to 
Figure 2.14: Process B microfabrication for integration of the nanoporous 
membrane and definition of the sample channel in SU-8. 
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secure the DSP to the tubing. Importantly, the process A workflow was intentionally 
developed to only incorporate Si/SiO2, does not rely on backside alignment, and only 
etches one side of the wafer. In other words, process A was designed as a CMOS 
compatible process (i.e., SiO2 on Si), and therefore the final wafer could be cleaned in 
aggressive piranha bath after through etching was completed. This cleaning step was 
significant as it removed residue within the through holes to mitigate any clogs in the final 
device. Finally, process A enabled device bonding. One side of the wafer was left with a 
Figure 2.15: Process C microfabrication for wafer level bonding, membrane release, 
and inlet/outlet integration.  
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smooth, thermally grown SiO2 layer which served as a suitable interface for the bonding 
procedure in process C.  
The infrared (IR) transmissibility of silicon was exploited to enable the wafer level 
alignment of the process A and B wafers in process C (Figure 2.15). Early iterations of the 
DSP microfabrication process deposited SU-8 on the inlet wafer (process A) to align the 
sample channels with the inlet holes. However, the rough Al2O3 layer did not adhere to the 
smooth SU-8 layer which resulted in batch delamination of the final devices. Modifying 
the process to deposit SU-8 on the Al2O3 enabled bonding, which motivated the use of a 
back-lit IR microscope to align the sample channels and inlet holes. This modification to 
the process demanded that the first pattern deposited on each process wafer was centered, 
hence the utilization of a maskless aligner to center each pattern on the wafers.  
2.5.1 Microfabrication Process in Brief 
The DSP mass exchanger is produced via batch microfabrication with three separate 
process flows, the first two accomplished in parallel on individual wafers and then a final 
process flow with processing steps carried out on the bonded wafer stack, including the 
incorporation of an inlet capillary and an outlet ESI emitter. Both process A  and B (Figure 
2.13 and Figure 2.14) begin with thermal oxidation of double side polished p-type <100> 
orientation silicon wafers (1-20 ohm-cm, Polishing Corp of America) resulting in a 3μm 
thick SiO2 mask layer on both sides of each wafer. Process A begins as 380 μm diameter 
holes are patterned in a layer of SPR 220 photoresist with photolithography Figure 2.13 
A2), and then in the SiO2 layer with a reactive ion etch (RIE) step (Figure 2.13 A3).  
Concentric 60 μm diameter holes in a layer of SPR 220 are patterned above the larger SiO2 
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patterned holes, followed by a deep reactive ion etching (DRIE) “Bosch” process carried 
out on the wafers for ~400 microns (Figure 2.13 A4). The photoresist is stripped, and 
another DRIE etch is carried out on the unmasked 360 μm patterned SiO2 layer with 
concentric partially etched 60 μm inlets until a through etch is achieved, resulting in the 
clog resistant counterbore capillary recess depicted on the inset image (Figure 2.13 A5). 
Process B begins as the active conditioning channel is patterned in SPR 220 (Figure 2.14 
B2) followed by a subsequent RIE etch in the SiO2 masking layer (Figure 2.14 B3). 
Afterwards, the wafer is cleaned and a ~5 micron thick film of aluminum is deposited on 
the side opposite the patterned SiO2, and subjected to an anodization process which creates 
a nanoporous alumina film with tunable pore diameters in the 10-50 nm range (Figure 2.14 
B4).44 Following the anodization, backside photoresist patterning of SU-8 3005 is carried 
out to define the sample channels (Figure 2.14 B5). Process C begins as the two wafers are 
bonded at 130 °C and 10 bar for 30 minutes (Figure 2.15 C1). A DRIE  process is carried 
out on the patterned conditioning channels down to the layer of SiO2, followed by two RIE 
steps (CHF3 followed by CF4) to open the barrier layer in the nanoporous membrane to 
allow fluidic transfer between sample and conditioning channel (Figure 2.15 C2). Between 
the first and second RIE step for opening pores, the devices are diced. Finally, inlet and 
outlet capillaries are positioned and glued into place within each counterbore capillary 
recess using a UV activated epoxy (Figure 2.15 C3).   
2.6 Fluidic Interface Package  
The DSP is packaged in a CNC machined polycarbonate or PEEK package which 
is designed to introduce a uniform flow of conditioning liquid across the top of the DSP 
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device at a relatively high flow rate (μL/hr of the sample flow vs mL/hr of the conditioner 
solution). As shown in the exploded view in Figure 2.16, a self-adhesive silicone gasket 
placed between the package and DSP sealed the conditioning flow against the topside of 
the DSP for continuous flow through the package. For superior chemical resistance when 
exploring conditioners such as acetonitrile, a PEEK package top was used, but for most 
applications a transparent polycarbonate package proved to be beneficial for identifying 
bubbles within the conditioning channel. Bubbles within the conditioner channel stop the 
diffusional transfer of species from the sample channel to the conditioner channel and 
render DSP conditioning ineffective.  
The fluidic interface package underwent two design iterations for improved mass 
exchanger performance. In the initial design, the conditioner flow and sample flow were 
Figure 2.16: An exploded view of the DSP fluidic interface package. 
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oriented in parallel but opposite directions, or in the “counterflow” orientation used for 
DSP prototyping (CHAPTER 3). CFD modeling guided an improved design in which the 
conditioner and sample flow paths are perpendicular to each other, i.e., in “crossflow” 
orientation which has improved DSP performance as discussed in section 2.7. Figure 2.17 
shows an isometric view of the assembled fluidic package along with CAD models of both 
orientations. For both iterations, a peristaltic pump provided conditioner flow at 50 mL/hr 




Figure 2.17: Cross section of DSP in the fluidic interface package with CAD 
schematics of both counterflow (first generation) and crossflow (second generation 
after performance optimization) flow configurations. 
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2.7 Model Guided Mass Exchanger Optimization 
During sample treatment, species within the sample channel are transported through 
the size selective membrane into the conditioner channel (or vice versa in the case of MS 
enhancing chemicals). Prior work reported that the transmembrane velocity in the mass 
exchanger was 9.2 μm/s within the 50 nm pores in the Al2O3 membrane. Based on the 
characteristic length of transport, i.e., a 5 μm membrane thickness, and this transmembrane 
velocity, the Peclet number for a species with a diffusion coefficient of 10-9 m2/s within the 
nanopores is ~0.022.34, 43 This indicates that within the nanopores, diffusion is the dominant 
transport mechanism. In both the sample and conditioning channels, the average velocity 
can be estimated as V=Q/A where Q is the flow rate and A is the cross-sectional area. 
Within the sample channel, with a length of 2.2 cm and a characteristic velocity of 8 mm/s, 
the Peclet number is ~105. The conditioner channel Peclet number is ~104 using the length 
of 11 mm and a characteristic velocity of 3 mm/s. Advection is dominant within both the 
sample and conditioner channels based on these large Peclet numbers, and therefore 
increasing the bulk mass transfer coefficient in either channel will enhance transport in the 
mass exchanger. However, increasing the mass transfer coefficient in the sample channel 
comes at a significant operational cost. Assuming the flow is fully developed (from both a 
hydrodynamic and mass transfer perspective) within the sample channel, the Sherwood 
number is constant, and only by reducing the characteristic length of transport can mass 
transfer efficiency improve. The sample channel height (5 μm) can be reduced to improve 
the resulting mass transfer coefficient, but the tradeoff is increased hydrodynamic 
resistance, which can lead to membrane failure due to an increased pressure loading across 
it. From a practical standpoint, reducing the sample channel height may also result in more 
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clogging events from debris with critical dimensions (i.e., minimum length dimensions) 
above the reduced height dimension. Further, prior work indicated that the dominant 
resistance to mass transfer in a similar mass exchanger geometry was convection within 
the conditioner channel.34, 43 The conditioner channel is easily modified without affecting 
device reliability, and therefore the flow structure within the conditioner channel was 
studied to reduce mass transfer resistance in the entire system.  
 In order to improve device efficiency in terms of salt removal and MS enhancing 
species infusion, the conditioner flow orientation was changed from a counterflow to a 
crossflow orientation relative to the sample channel, as shown in Figure 2.18, to reduce the 
characteristic length over which the mass transfer boundary layer grew. The design was 
qualified with simulations, and experimental validation of the improved device 
performance was carried out prior to applying the optimized DSP to more complex 
samples, e.g., those taken directly from a cell culture. 
Figure 2.18: Counterflow and crossflow orientations for the DSP mass exchanger. A 
simple change in package geometry modified the flow orientation to enhance the 
mass transfer coefficient by over 150%. 
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The short distance between the conditioner flow inlet along with a step change in 
geometry upon entering the conditioner channel creates a system in which the flow is 
developing from both a hydrodynamic and mass transfer perspective, necessitating the use 
of simulations to accurately predict the mass transfer coefficient. Both two-dimensional 
(2D) and three-dimensional (3D) simulations were carried out, and it was determined that 
a full domain simulation was necessary for effectively estimating the mass transfer 
coefficient, especially in the counterflow orientation. Figure 2.19 shows the growth of the 
concentration boundary layer by plotting the surface corresponding to the 99% free stream 
Figure 2.19: Simulation domain and iso-surface (red) corresponding to 1% of the 
boundary value of concentration (proxy for the upper edge of the concentration 
boundary layer) for the counterflow orientation with a constant concentration 
(C=300 mM) boundary condition at the top (facing the conditioner flow) membrane 
surface. The 3D nature of the boundary layer growth confirmed that 2D simulations 
would not capture the relevant phenomena nor estimate the mass transfer 
coefficient accurately. 
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concentration value. The three-dimensional nature of the boundary layer affects the local 
mass transfer coefficient, motivating the use of a full domain simulation to effectively 
estimate the mass transfer effects. 
The convective flux can be estimated within the conditioner channel using equation 
(2.1): 
𝐽𝑐
′′ = ℎ𝑐(𝐶𝑚𝑒𝑚𝑏𝑟𝑎𝑛𝑒 − 𝐶𝑓𝑟𝑒𝑒𝑠𝑡𝑟𝑒𝑎𝑚) (2.1) 
where 𝐽𝑐
′′ (mol/s/m2) is the flux from the sample channel into the conditioner channel, ℎ𝑐 
(m/s) is the convective mass transfer coefficient in the conditioner channel,  𝐶𝑚𝑒𝑚𝑏𝑟𝑎𝑛𝑒 
(mol/m3) is the analyte concentration on the top surface of the membrane, and 𝐶𝑓𝑟𝑒𝑒𝑠𝑡𝑟𝑒𝑎𝑚 
(mol/m3) is the analyte concentration far from the membrane in the free stream outside of 
the concentration boundary layer. The concentration far from the membrane surface was 
assumed to be 0 mol/m3, and this was confirmed with the simulation result. The position 
where C=3 mM (1% of the surface value) is shown in Figure 2.19 (red) is taken to be the 
location of the concentration boundary layer edge. The boundary layer does not reach the 
top edge of the domain, therefore it is reasonable to assume that C approaches 0 mol/m
3 







 The simulations were carried out in the COMSOLTM software using coupled 
modules of Laminar Flow and Transport of Dilute Species. For each simulation, the 
conditioner channel was simulated with the following depth x width x length dimensions: 
600 μm x 4.5 mm x 11 mm. A plane on the bottom of the channel with width x length 
dimensions of 200 μm x 11 mm represented the area of the membrane where active analyte 
exchange occurs with the sample channel. Along this plane, either a constant flux or a 
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constant concentration boundary condition was implemented to establish a range of 
potential mass transfer coefficients. A total of four simulations were carried out to estimate 
ℎ𝑐: two in counterflow orientation with either a constant flux or constant concentration 
boundary condition, and again two in crossflow with the same boundary conditions. For 
each simulation the inlet and outlet to the conditioner channel were modeled as 100 μm tall 
strips spanning the entire width of the appropriate side walls to represent the area between 
the compressed silicone gasket within the fluidic package and the Si top plate of the mass 
exchanger, where conditioning flow enters or exits the package (Figure 2.17). At the inlet, 
species concentration was set to 0 mol/m3 and the flow was introduced as a uniform plug 
with the average velocity calculated as V=Q/A where Q is the conditioner flow rate (50 
mL/hr) and A is the inlet cross-sectional area, 100 μm x 11 mm in crossflow and 100 μm 
x 4.5 mm in counterflow. At the outlet, pressure was set to ambient and species were free 
to transport out of the domain. Water at 25 °C was used as the working fluid, and the binary 
diffusion coefficient (DAB) was set to 1x10
-9 m2/s to capture a representative value of the 
diffusion coefficient for relevant species transport, e.g., salts and biomolecules. A mesh 
convergence study showed that directly over the sample channel, elements of a maximum 
size of 5 μm were required with a growth rate of 1.03 for the rest of the domain. The 
maximum element size in the entire domain was set to 30 μm. Values of the average mass 
transfer coefficient were used to confirm mesh convergence. 
Figure 2.20 shows the resulting mass transfer coefficient calculated according to 
equation 2.2 along the center of the sample channel as a function as sample channel length. 
The surface average value from each simulation is written above the respective trace. In 
counterflow, the mass transfer coefficient increases to a maximum within 500 μm of the 
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entrance and then continuously decreases along the sample channel. The step change 
geometry at the entrance results in a stagnation zone at the entrance of the channel, but as 
the velocity just above the membrane increases, the mass transfer boundary layer thickness 
reaches a minimum and the mass transfer coefficient reaches a maximum. The mass 
transfer boundary layer then grows along the length of the channel, causing the mass 
transfer coefficient to decrease continuously. The profile of the mass transfer boundary 
layer in the counterflow orientation is shown in the side view in Figure 2.19. The minimum 
thickness of the boundary layer corresponds to a maximum mass transfer coefficient. In 
the counterflow geometry at the edges of the sample channel, the mass transfer coefficient 
is on average higher than at the center because the boundary layer is thinner towards the 
Figure 2.20: Mass transfer coefficient as a function of channel length along the 
centerline of the sample channel. Note that the displayed mass transfer coefficient 
value is an average across the entire sample channel area. 
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edge. Due to the 3D nature of boundary layer growth in counterflow, the edge regions of 
the sample channel have lower resistance to mass transfer and therefore a higher average 
mass transfer coefficient. 
 Crossflow orientation results in a 200 to 300% increase of the surface averaged 
convective mass transfer coefficient. Although the average flow velocity within the 
channel is actually lower in crossflow (3 mm/s in crossflow vs 8 mm/s in counterflow) 
because of a much greater cross sectional area for the same volumetric flow rate, the 
average thickness of the mass transfer boundary layer is smaller across the entire sample 
channel resulting in a higher mass transfer coefficient. The reason for this is twofold: 1) 
the small stagnation zone at the entrance region in counterflow is no longer in an active 
mass transfer area in crossflow 2) the mass transfer boundary layer is much smaller across 
the active transport area due to a shorter development length in crossflow (200 μm in 
crossflow vs 11 mm in counterflow).  
 A design change in the fluidic package allowed for crossflow orientation mass 
exchanger operation with no other changes to the system (Figure 2.17). The enhanced mass 
transfer was confirmed by comparing treatment of control samples consisting of phosphate 
buffered saline (PBS) and cytochrome c (Cyt c). Comparison of MS spectral signatures for 
treatments of 2xPBS (274 mM NaCl, 5.4 mM KCl, 20 mM phosphate buffer) with 2.5 μM 
Cyt c treated with 1% acetic acid (AA) in both the crossflow and the counterflow 
orientations clearly indicates the superiority of mass transfer (and thus enhanced interfering 
salt removal) in crossflow. In counterflow, the Cyt c signal is masked by adducted peaks 
while the crossflow treatment reveals multiple charge states associated with Cyt c with 
reduced background noise as shown in Figure 2.21.  
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Throughout the rest of this thesis DSP is employed in both the counterflow and the 
crossflow orientation. The counterflow orientation DSP is used to demonstrate the 
advantageous effects that active sample conditioning has on real-time ESI-MS analysis in 
most of CHAPTER 3, but the later results in this chapter (Section 3.5) and all of the results 
in CHAPTER 4 are from DSP in the optimized crossflow orientation. The reason that a 
sub-optimal design was applied in CHAPTER 3 is because the evidence of insufficient salt 
removal in the results presented in Sections 3.2-3.4 are what motivated the detailed study 
of the DSP mass exchanger. In other words, the model guided optimization presented here 
was carried out after the experiments presented in the early sections of CHAPTER 3.  
  
Figure 2.21: MS spectra comparison of counterflow and crossflow DSP treatment 
for sample with 2.5 μM Cyt c in 2xPBS. Counterflow treatment reveals a cluster of 
heavily adducted peaks around the expected +9 protonation state and overall a 
very noisy spectrum with significant background due to salt in the sample. Mass 
spectra for crossflow treatment are much cleaner with less background chemical 
noise and two distinct protonated +8 and +9 charge states associated with Cyt c, 
indicating higher levels of salt removal during treatment. 
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CHAPTER 3.  
DSP ANALYTICAL CHARACTERIZATION 
Inline, rapid analysis is important to enable in operando feedback and process control 
for quantitative monitoring methods in the biomanufacturing field. Electrospray ionization 
mass spectrometry (ESI-MS) is a suitable candidate for inline analysis due to its broad 
molecular weight coverage, sensitivity, and a possibility for preserving structure/folding 
and non-covalent interactions of biomolecular complexes through “soft-ionization”.22, 45, 46 
ESI-MS requires no labeling of biomolecules, allowing not only monitoring of target 
biomolecules, but also identification of unknown bio-analytes. However, direct ESI-MS 
analysis of biological samples is difficult due to the need for sample preparation prior to 
analysis. Inorganic salts found in high abundance in cell cultures suppress the signal 
associated with biomolecules, reducing ESI-MS measurement sensitivity and making 
identification challenging. Typically, techniques such as high performance liquid 
chromatography (HPLC) are employed upstream of ESI-MS both to remove compounds 
that interfere with the analysis and to separate and assist in identifying components of 
complex biomolecule mixtures. Due to the large time delay associated with these 
separation methods, real-time ESI-MS monitoring of cell cultures has been largely 
unexplored.  
In this chapter, real-time DSP ESI-MS analysis is explored and its performance metrics 
are defined and assessed under different conditions. The experiments were designed to 
probe active sample conditioning for enhanced MS analysis. Organic acids and 
supercharging molecules are of particular interest as conditioning agents for improving the 
DSP approach for ESI-MS analysis.47-49 A prototype DSP with counterflow orientation 
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sample treatment is applied to a range of high salt-content solutions that served as proxies 
to biologically relevant solutions. These results demonstrate that in addition to removing 
salts during treatment, transferring conditioners into the treated sample can improve limit 
of detection (LOD) by an order of magnitude and enable multicomponent detection, a key 
milestone for monitoring bioreactors which have a range of soluble biomolecules present 
in low abundance. In the improved crossflow design, varying the concentration of organic 
acids is shown to improve protonation effects and enable the detection of high molecular 
weight (~50 kDa) monoclonal antibody (mAb) fragments, emphasizing that active 
conditioning improves the ability to detect a broad range of biomolecules.  
3.1 Experimental Setup for Real-time ESI-MS 
The experimental configuration used for qualification of the DSP for real-time ESI-
MS is shown in Figure 3.1. A sample of known composition was drawn into a 50 μL syringe 
(HamiltonTM Gastight 50 or 100 μL) and infused with a syringe pump at 35 μL/hr through 
a length of fused silica capillary with a 75 μm inner diameter, which is attached to the inlet 
capillary of the DSP with Upchurch fittings in a ValcoTM union. On the tip of the syringe, 
an electrical connection is made to the probing end of a picoammeter. The ground end of 
the picoammeter is then attached to the ground of the mass spectrometer for continuous 
ESI current monitoring. The DSP in the fluidic interface package was positioned 3-5 mm 
away from the Bruker micrOTOF MS inlet, which is held at a negative bias to complete 
the circuit. During all experiments, spray current was kept between 10 and 20 nA at a 
steady value to ensure similar ESI conditions at the MS inlet.  
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 Conditioning flow is delivered at 50 mL/hr with a peristaltic pump, which draws 
from a liquid reservoir through silicone tubing. Conditioning liquid then travels to the 
device package, where the connection is made with Upchurch fluidic fittings into the DSP 
package (section 2.6). For the counterflow experiments in sections 3.2, 3.3, and 3.4 
conditioning solution travels in the opposite direction of sample flow along the top side of 
the etched conditioning channel, separated from the sample channel within DSP by the size 
selective nanoporous membrane. For some results in this chapter (section 3.5) the 
crossflow orientation fluidic package was used. More details on the packages are provided 
in section 2.6. 
 
Figure 3.1: The DSP experimental setup for analysis with the Bruker 
MicrOTOF MS. This system was used for all experiments using this MS, 
including those in CHAPTER 4. 
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3.2 Salt Removal and Active Sample Conditioning 
Inorganic salts interfere with positive mode electrospray mass spectrometry (ESI-
MS) by suppressing the MS signal associated with analyte molecules. Removal of salts 
promotes charging of molecules with only protons, i.e. protonation, instead of charging 
molecules via metal cation adduction. In addition to cation adduction, neutrals (e.g. KCl, 
NaCL, H2O molecules) can attach to the ionized analytes, forming “clusters” (see section 
1.3.2). The signal at any fully protonated charge state associated with a given biomolecule 
becomes masked by the signal of the same or other molecules whose ions carry adducted 
and clustered species, making it impossible to identify the biomolecule via MS.31, 33, 34, 50-
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DSP enhancement of ESI-MS analysis was explored through comparison of the 
effect of four different active conditioning solutions. Each conditioning solution contained 
1% acetic acid  (AA) to facilitate the protonation of compounds53 and three of the 
conditioning solutions contained one additional ESI-MS enhancing chemical: ammonium 
acetate, 3-nitrobenzyl alcohol, or methanol. Ammonium acetate  has been reported to 
increase the acidity in the electrospray plume for enhanced protonation54 and reduced 
formation of salt adducts.55, 56 While acetic acid and ammonium acetate enhance 
protonation, the other conditioners were explored for their charge state shifting effects. A 
shift (increase) in the charge state distribution was expected to increase sensitivity in ESI-
MS analysis while also enhancing advanced tandem mass spectrometry applications.47-49, 
57  Supercharging molecule 3-nitrobenzyl alcohol (m-NBA) in concentrations from 1-20% 
has been reported to increase charge state distribution in non-denaturing solutions. 
Although the mechanism is not completely settled, it is suggested that supercharging occurs 
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due to the low volatility and low surface tension of the super charging agent, a combination 
that promotes the Coulombic droplet fission process.57, 58 Finally, methanol (MeOH) can 
shift charge state distribution towards a lower m/z spectral range due to a denaturing of 
biomolecules which results in exposing more locations for protonation.49  
A solution of 100 mM KCl with 5 μM cytochrome c (Cyt c) was used to carefully 
characterize the effect of active sample treatment. In order to maintain relevance to cell 
manufacturing, the salt level used is similar to that expected in a bioreactor,29 and Cyt c is 
an appropriate model protein in the mass range (~12 kDa) of signaling molecules secreted 
from cells, such as cytokines, that are expected to be CQAs for cell state.8, 23, 37, 39 When 
untreated, the spectra obtained for ESI-MS of 100 mM KCl with 5 μM Cyt c (Figure 3.2) 
has no peaks associated with Cyt c, indicating that the added KCl levels are high enough 
to render MS analysis incapable of identifying the protein. This result demonstrates that 
the high salt content in bioreactors will mask biomolecule signals in direct ESI-MS 
analysis. As discussed in CHAPTER 1, (Section 1.3.2, Figure 1.5) salt concentrations need 
to be reduced to below about 1 mM for identification of Cyt c at a concentration of 5 μM. 
Figure 3.2 Resulting mass spectra from direct infusion ESI-MS through DSP of a 
solution with 100 mM KCl and 5 μM cytochrome c without treatment, i.e. empty 
conditioning channel. No characteristic cytochrome c peaks are visible due to salt 
which causes adduction and clustering that masks the signal of the protein. 
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Therefore, at least 99% of the KCl in the solutions tested here were removed by DSP. In 
cell monitoring applications, analyte concentrations could be lower than 5 μM which is 
why a highly selective mass exchanger, such as DSP, is necessary to remove salt to a 
sufficient degree while retaining biomolecules of interest through size selective separation.  
 The benefit of DSP online active sample treatment is made evident by comparing 
the spectra of an untreated sample (Figure 3.2) and a sample with treatment (Figure 3.3) 
using a 1% acetic acid (AA) conditioning solution.  The mass spectra shown in Figure 3.3 
is characteristic of Cyt c ionized in low salt content solutions. The most intense peak 
(m/z ~ 1374) is associated with Cyt c molecules charged via addition of nine protons, 
referred to as the +9 charge state. The appearance of Cyt c spectral peaks in online analysis 
of a high salt solution occurs as a result of several mechanisms. First, the removal of salt 
reduces metal cation adduction of the protein, so that the protein is charged via protonation. 
Salt removal also eliminates the formation of cluster peaks, reducing charge competition 
and corresponding signal suppression. Finally, addition of AA into the sample further 
Figure 3.3 Resulting mass spectra from direct infusion ESI-MS treated by DSP of a 
solution with 100 mM KCl and 5 μM cytochrome c with 1% AA treatment reveals a 
strong cytochrome c signal. 
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increases the rate of protonation due to the increased proton concentration in acidified 
solution.  
Adding 40 mM ammonium acetate to the conditioning solution increases the 
intensity of the largest Cyt c associated peak from ~105 with AA only treatment
 (Figure 
3.3) to ~106 with no shift in charge state distribution (Figure 3.4). While addition of 
ammonium acetate further enhances protonation54 and mitigates salt adducts,56 ammonium 
acetate does not change the surface tension and has little to no denaturing effect on the 
protein so there is no apparent impact on the charge state. For this experiment it is also 
unclear whether intensity is an indication of improved sample conditioner efficacy. With 
Cyt c at the 5 μM concentration level, later experiments show that MS signal intensity 
varies while signal to noise ratio remains the same, suggesting that the signal is saturated 
at the 5 μM level and that signal intensity may be a poor metric for DSP performance (see 
section 3.3). 
In contrast, adding supercharging molecule m-NBA at 2% to the conditioning flow 
results in a significantly shifted charge state distribution (Figure 3.5). This shift in charge 
state reveals Cyt c with 15 protons attached as the most dominant, referred to as the +15 
Figure 3.4 Resulting mass spectra from direct infusion ESI-MS treated by DSP of a 
solution with 100 mM KCl and 5 μM cytochrome c with 1% AA, 40 mM ammonium 
acetate treatment reveals a strong cytochrome c with improved signal intensity. 
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charge state, at about m/z 824. For non-denaturing/super-charging treatment types like AA 
or ammonium acetate (spectra shown in Figure 3.3 and Figure 3.4) the +9 charge state is 
most dominant, at approximately m/z 1374. Although not producing the same maximum 
peak intensity as ammonium acetate, m-NBA causes a marked increase in the prevalence 
of peaks corresponding to the highly charged protein. This suggests the possibility of using 
m-NBA treatment for higher molecular weight proteins that would usually be outside the 
range of a given mass spectrometer. For instance, the Bruker MicrOTOF time-of-flight 
mass spectrometer used in these experiments has a mass to charge ratio (m/z) range of 
30 – 5000 m/z. Thus, increasing the maximum number of charges placed on a protein from 
10 to 20, for example, would raise the size of the largest detectable protein from 50 kDa to 
100 kDa. The impact of supercharging is also seen in its potential for improved sensitivity. 
This is because tuning the ion transfer voltages in a mass spectrometer to acquire signals 
over the entire available m/z range sacrifices sensitivity compared to that obtainable when 
tuned for a smaller m/z range. As seen in Figure 3.5, super charging compresses the range 
of m/z values for Cyt c peaks enabling better use for the instrument capabilities for 
biomolecular detection.  
Figure 3.5 Resulting mass spectra from direct infusion ESI-MS threated by DSP of 
a solution with 100 mM KCl and 5 μM cytochrome c with 1% AA, 2% m-NBA 
treatment shifts to a higher charge state distribution. 
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Addition of 50% methanol (MeOH) also has a significant effect on the charge state 
distribution (Figure 3.6). This treatment results in a spectra in which the +14 charge state 
(m/z ~883) is most abundant, which suggests that the effects of m-NBA and MeOH are not 
identical. Methanol denatures the protein, revealing more sites for protons to attach, which 
results in a shift in the spectrum to a higher charge state distribution. Although MeOH, like 
m-NBA, has a lower surface tension than H2O, it is also more volatile than H2O. Therefore 
it does not yield the same increase in droplet fission events that m-NBA produces.49, 58 
Further, due to a lower solubility limit of inorganic salts within MeOH, continuous flow 
analysis is difficult using MeOH as an active conditioner.59 As MeOH is exchanged into 
the sample, salt precipitates form. These precipitates eventually clog the sample channel or 
the ESI emitter, causing the DSP to cease operation.  
3.3 Signal to Noise Ratio and Limit of Detection Enhancement  
To quantify the impact of DSP active sample treatment, MS signal to noise ratio 
(SNR) and limit of detection (LOD) were studied. Samples containing varying Cyt c 
Figure 3.6 Resulting mass spectra from direct infusion ESI-MS treated by DSP of a 
solution with 100 mM KCl and 5 μM cytochrome c with 1% AA, 50 % methanol 
also increases the average charge state, but long term operation is hindered due to 
increased inorganic salt precipitation clogged DSP. 
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concentrations (0.25, 0.5, 1.0, 2.5, 5, and 10 μM) in 50 mM KCl were treated with two 
conditioning solutions, 1% AA or 1% AA, 2% m-NBA, to explore what effect active 
conditioning has on DSP-MS in terms of SNR and LOD.  These experiments were designed 
to investigate if supercharging molecules enhance ESI-MS detection of proteins at low 
concentrations because the effect of ammonium acetate on resulting ESI-MS was subtle, 
and methanol hindered continuous DSP operation. 
The addition of m-NBA to the active conditioning solution increases SNR across 
multiple charge states. Figure 3.7 illustrates this point by plotting the highest and fifth 
highest SNR as a function of Cyt c concentration (there are multiple SNRs associated with 
Figure 3.7: Highest across all peaks and 5th highest signal-to-noise ratio (SNR) 
values of identified Cyt c peaks within samples (50 mM KCl with: 0.25, 0.5, 1.0, 
2.5, 5, & 10 μM Cyt c) treated with 1% AA vs 1% AA 2% m-NBA. The m-NBA 
treatment reveals multiple charge states at all concentrations.  
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Cyt c due to existence of multiple charge states). Here, signal to noise ratio is defined as 
SNR=ICyt c/Iavg,, where the ICyt c is the intensity (%) of an identified Cyt c peak and Iavg is 
the averaged intensity (%) of all peaks within a window +/- 0.3 m/z of the identified peak. 
This definition gives a local SNR value for every protonated Cyt c peak. An SNR above 
~2.5 corresponds to a distinguishable, fully protonated Cyt c peak. These results are 
presented in this manner to demonstrate that m-NBA treatment improves the LOD and 
increases the SNR for detected molecules across multiple charge states, which enables 
easier identification of low concentration biomolecules in complex mixtures.  
Active treatment with m-NBA drastically improves the LOD, i.e., the lowest 
concentration for which the SNR of a peak associated with fully protonated Cyt c is greater 
than 2.5. For Cyt c in 50 mM KCl, this LOD is improved by an order of magnitude, from 
2.5 μM to 250 nM. To illustrate the qualitative effect that m-NBA has on the resulting 
Figure 3.8:  DSP 1% AA treatment -ESI-MS of 50 mM KCl with 1 μM Cyt c 
shows no characteristic Cyt c spectral features. The protein is unidentifiable 
after standard desalination without active sample conditioning.  
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spectra, DSP nanoESI-MS analysis of 1 μM Cyt c in 50 mM KCl with 1% AA conditioning 
solution (Figure 3.8) and 1% AA and 2% m-NBA (Figure 3.9) is shown. The difference in 
the two spectra highlights the significant effect addition of m-NBA has on LOD. With 1% 
AA treatment (Figure 3.8), no distinguishable protonated Cyt c peaks are visible, while 
treatment with 1 % AA 2% m-NBA produces five distinct peaks associated with 
completely protonated species (Figure 3.9).  
At 2.5 μM Cyt c conditions, where use of both conditioning solution compositions 
in DSP successfully reveal the protein signature, m-NBA treatment enhances SNR across 
multiple charge states far above the levels obtained with AA only treatment. With very 
high SNR peaks across a range of multiply charged states, identification of biomolecules 
is easier, and applications which can benefit from biomolecule structural information are 
Figure 3.9:  DSP 1% AA, 2% m-NBA treatment-ESI-MS of 50 mM KCl with 1 
μM Cyt c reveals multiple charge states for identification of the protein, which 
shows that the active sample conditioning can improve both signal to noise ratio 
and limit of detection (sensitivity). 
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enabled through the use of tandem (MS/MS) mass spectrometry that performs best with 
highly charged species.48  Although for both 5.0 and 10.0 μM Cyt c concentrations 1% AA 
treatment produces a very high SNR for the highest intensity peak, m-NBA treatment again 
creates higher average SNR values. These levels of Cyt c concentration (5, 10 μM) are 
approaching the point where signal saturation was observed, such that MS measurements 
of abundance is not dependent on treatment type, muting the impact of active sample 
conditioning. However, the ability to detect low concentration biomolecules (i.e. <2.5 μM 
Cyt c) through DSP’s active sample conditioning with m-NBA is the most important 
conclusion of these experiments. The results emphasize that DSP has the capability for 
detection and/or discovery of low concentration biomolecules because of active sample 
treatment via inline introduction of ESI-MS enhancing compounds. This type of detection 
is usually only possible with offline methods like HPLC-MS, rendering DSP a unique and 
powerful tool for in operando cell-health monitoring.  
The concentration of some CQAs in bioreactors is significantly lower than those 
explored here. Therefore, the ability to detect even lower concentration biomolecules 
enabled by DSP treatment is critical for ESI-MS application to cell manufacturing quality 
monitoring. Importantly, these experiments were performed on a Bruker MicroTOF MS 
which was available for device development and testing. Unfortunately, this MS does not 
possess the capabilities or sensitivity of more advanced MS instrumentation available for 
bioanalysis. For example, an improved dynamic range on updated instruments enables 
lower concentration species to be detected, especially when in the presence of higher 
concentration biomarkers. On the Bruker instrument the LOD for a Cyt c solution is 
roughly 10 nanomolar, while on advanced instrumentation picomolar and even femtomolar 
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sensitivity is expected. Furthermore, improved resolution and tandem mass spectrometry 
would also enable more complete CQA characterization. The Bruker micrOTOF MS only 
allows accurate mass predictions of species. This system does not possess isotopic 
resolution for resolving charge state or protein conformation which makes untargeted 
identification of CQAs challenging. Updated mass spectrometers also utilize tandem mass 
spectrometry for protein sequencing and biomolecular identification, which are key to 
enabling biomolecular discovery. In other words, extrapolation of LODs with the Bruker 
MS illustrates the power of the active sample conditioning protocol, but in cell culture 
applications more advanced MS instruments will improve the DSP enabled ESI-MS 
characterization of CQAs significantly. In advanced therapy applications the limitation 
may be on the analytical instrument, not on the DSP sample conditioning protocol.  
3.4 Simultaneous Identification of Multiple Proteins  
In any bioreactor there are a multitude of dissolved biomolecules which are difficult 
to detect simultaneously without chromatographic separation or other sample preparation 
techniques such as digestion. To assess the DSP’s capability for multiple biomolecule 
detection, experiments were performed with a high salt content buffer mixture, phosphate-
buffered saline (1xPBS: 137 mM NaCl, 2.7 mM KCl, 1.0 mM Na2HPO4, and 1.8 mM 
KH2PO4), containing 5 μM of  interleukin 6 (IL-6), interleukin 8 (IL-8), and Cyt c. This 
multi-component mixture was then treated with the two different active sample 
conditioning strategies described in the prior section (3.3) to investigate the effect that 
super charging molecules have on multi-component detection.  With molecular weights of 
~8 kDa (IL-8), ~12 kDa (Cyt c), and ~21 kDa (IL-6), the mixture of these molecules is a 
realistic proxy for cytokines, which are known to be indicative of cell health,37, 39 in a 
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solution that has multiple inorganic compounds in concentrations representative of a 
bioreactor environment.29 As expected, the baseline ESI-MS of 5 μM IL-6, IL-8, and Cyt c 
in 1x PBS without DSP treatment produces no meaningful detection of any biomolecules 
(Figure 3.10). When 1% AA treatment was used, only IL-6 was detected (Figure 3.11), 
whereas treatment with 1% AA 2% m-NBA yielded detection of both IL-6 and Cyt c 
(Figure 3.12).   
During treatment with 1% AA as the conditioning solution, removal of inorganic 
compounds and acidification of the sample reduces chemical noise associated with salt 
adducts and clusters, and IL-6 can be detected (Figure 3.11). The highest concentration of 
salt in PBS is NaCl at 137 mM, which is higher than the salt levels explored in the 
experiments described in earlier sections (100 mM Figure 3.2-Figure 3.6, 50 mM Figure 
3.7-Figure 3.9). Again, referring to the minimum sample treatment requirements for ESI-
MS explored in CHAPTER 1 (Section 1.3.2, Figure 1.5), it can be estimated that the DSP 
is removing over 99% of the salts present in order to reveal the signal associated with IL- 6.  
However, the SNR is low, and peaks formed via salt adducts are visible at higher m/z 
Figure 3.10: Mass spectra produced via direct infusion ESI-MS treated by DSP 
of untreated 1xPBS with 5 μM Cyt c (12 kDa), 5 μM IL-6 (21 kDa), and 5 μM 
IL-8 (8.4 kDa) shows no identifiable peaks associated with protonation of 
biomolecules.  
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values along with each protonated peak, indicating not fully sufficient salt removal with 
DSP operating in counterflow. These results motivated the optimization of DSP from a 
mass transfer perspective as discussed in Section 2.7.  
Treatment with 1% AA, 2% m-NBA reveals high SNR, fully protonated Cyt c and 
IL-6 peaks, but IL-8 is not observed (Figure 3.12). As the smallest of the analytes, IL-8 
Figure 3.11: Mass spectra produced via direct infusion ESI-MS through DSP 
with 1% AA treatment of 1xPBS with 5 μM cytochrome-c (12 kDa), 5 μM IL-6 
(21 kDa), and 5 μM IL-8 (8.4 kDa) reveals multiple charge states associated with 
IL-6 only.  
Figure 3.12: Mass spectra obtained via direct infusion ESI-MS through with 1% 
AA, 2% m-NBA treatment of 1xPBS with 5 μM cytochrome c (12 kDa), 5 μM 
IL-6 (21 kDa), and 5 μM IL-8 (8.4 kDa) reveals fully protonated charge states of 
cytochrome c and IL-6. IL-8 is not detectable, likely due to its unintended 
removal through the membrane due to low molecular weight (small size). 
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may have suffered more parasitic loss (cross-over to the conditioner flow) in the DSP mass 
exchanger than larger in size Cyt c and IL-6.34 This result further emphasizes that active 
sample treatment with m-NBA is a very useful for reducing chemical noise due to metal 
cation adduction and salt cluster formation. These promising results demonstrate that DSP 
with active sample treatment enables the detection of multiple biomolecules in a high salt 
content mixture, at the concentration levels relevant to cell manufacturing applications.  
3.5 High Molecular Weight Tuning 
Detecting high molecular weight biomolecules has important applications in nascent 
cellular therapy workflows because some of the CQA biomolecules or paracrine factors 
that signal therapeutic responses are well above the 21 kDa (IL-6) upper limit explored in 
section 3.4. Additionally, well established fields such as pharmaceutical biologics rely 
heavily on the ability to detect and characterize large, complex proteins such as monoclonal 
antibodies (mAbs). Preserving the state of these proteins to capture non-covalent 
interactions or post translational modifications is a key advantage of ESI-MS as an analysis 
technique, but these molecules can be difficult to detect in their intact state due to the 
limited m/z ranges on mass spectrometers. As discussed, supercharging molecules like m-
NBA are effective for improving signal to noise (SNR) and limit of detection (LOD), but 
these benefits are limited. It was observed that when increasing the concentration of m-
NBA above 2% in the conditioner channel that the resulting spectra was dominated by m-
NBA and associated clusters, although it has been reported that m-NBA has advantageous 
effects and concentrations well above this level.47-49, 57, 60 The negative effect of m-NBA 
clusters was even more drastic in the later iteration of DSP with crossflow orientation 
sample treatment, which not only improved removal of parasitic species, but also improved 
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the transfer of conditioning agent m-NBA to the sample. The presence of m-NBA clusters 
was not observed in the initial proof-of-concept, SNR, and LOD experiments presented in 
previous sections 3.2, 3.3, and 3.4 where DSP was operated in counterflow orientation at 
the 2% m-NBA conditioner level. However, as it was observed that m-NBA at levels above 
1% in the conditioner was found to have a negative effect in crossflow, other means of 
improving MS sensitivity to high weight molecules were explored. 
 As shown with MeOH active treatment (Figure 3.6), the denaturing of a protein 
enhances the protonation efficiency because more sites for ionization are revealed. 
However, most organic solvents are not compatible with DSP due to salt precipitates 
formed when the solvent transferred into the sample channel and interacted with untreated 
media. Another common method used to denature a protein is changing the solution pH. 
In positive mode ESI, reducing the pH also improves ESI-MS analysis as lower pH 
solutions are inherently more likely to produce protonated species due to a higher 
prevalence of free protons. For these reasons, the concentration of acetic acid (AA) was 
varied in the conditioner channel to observe the results on biomolecule detection.  
Figure 3.13 shows the treatment of 50 mM KCl, 5 μm Cyt c with varying levels of 
AA in the conditioner channel. For these experiments, DSP was operated in the crossflow 
orientation which improved salt removal and, importantly, AA transfer to the sample. As 
expected, signal associated with Cyt c is visible with the “baseline” 1% AA treatment (top) 
in Figure 3.13. Increasing the AA to 5% shifted the spectra to higher charge states and 
improved the SNR of the observed charge states in the m/z range below 1300. Increasing 
from 5% to 10% did not result in any notable qualitative or quantitative changes in the 
spectra. The increased AA concentration from 1% to 5% improves biomolecular detection 
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due to a combination of improved ionization from higher relative concentrations of protons 
and moderate protein denaturing in the low pH solution. However, this trend has 
diminishing returns at 10% AA where solid precipitates formed in the sample channel 
which hindered continuous operation of DSP. In addition, the higher acidity also caused 
material compatibility issues. Notably, the self-adhesive gasket used for sealing the 
conditioner channel was visibly damaged after ~2 hours of use.  
To demonstrate the effect that tuning the conditioner composition has on practical 
applications a monoclonal antibody (mAb) fragment with a molecular weight of ~50 kDa 
was used as a testbed. This antibody fragment is part of the OMG 18 RV anti-frizzzled 
mAb which has been shown to have important roles in the WNT signaling pathway with 
Figure 3.13 DSP-ESI-MS analysis of 50 mM KCl, 5 μM cytochrome-c with varying 
concentrations of acetic acid (AA). Increasing the concentration of acetic acid in the 
conditioner channel from 1% v/v to 5% enhances the protonation of the protein, 
producing a very clear charge state distribution. Increasing the concentration from 
5% to 10% does not appear to affect the signal.  
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strong anti-tumor properties.61 The protein was obtained in an isolated format in 1X PBS 
at approximately 800 nm concentration with 2% glycerol to aid in suspension. This solution 
was treated with DSP in the crossflow orientation using a conditioner solution of 5% AA, 
1% m-NBA. The resulting spectrum from direct DSP-ESI-MS analysis of the protein is 
shown in Figure 3.14. As these experiments were conducted on the Bruker MicroTOF 
instrument, detecting a protein of this size proved to be challenging. The lack of isotopic 
resolution made it impossible to determine the charge state associated with each peak. It is 
also unclear if the peaks associated with each parent peak are associated with adducts, 
clusters, or protonated species. To aid in visualizing the MS spectra appearance of 
incompletely resolved protein, a theoretical charge state distribution for a completely 
protonated 50 kDa protein is overlaid on the spectra in Figure 3.14. The spectral peaks 
align well with the predicted charge states for a completely protonated species, indicating 
 
Figure 3.14: 5% AA, 1% m-NBA treatment of 1X PBS, 2% glycerol, 800 nM OMP 
18 RV anti-frizzled mAb fragment (50 kDa). The theoretical charge state “ruler” for 
a 50 kDa protein is overlaid on top of the spectra for visualization purposes.  
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that the protein was detected. However, this “semi-targeted” approach is only possible if 
the identity of the protein is known a priori, but these results demonstrate that the active 
conditioner composition plays a key role in aiding in the detection of a broad range of 
biomolecules. The analysis of larger mAbs is commercially and clinically relevant as these 
molecules already have substantial use by pharmaceutical industry unlike nascent 
advanced therapeutics (e.g. cell therapies). Already there are real-time approaches for mAb 
monitoring using Raman spectroscopy, but DSP provides a unique ability to characterize 
these molecules as they are produced using MS sensing. Raman requires significant data 
training to detect a known molecule, and subtle aspects of the molecules’ structure 
(e.g., oxidation) and folding are not always captured in the data output.10 On the other hand, 
ESI-MS when coupled with tandem mass spectrometry enables complete mAb 
characterization including structural conformation and sequencing. Therefore, the DSP 




CHAPTER 4.  
DSP APPLICATION TO CELL STATE ANALYSIS 
Cell cultures and bioreactors are transient and heterogenous environments. Probing 
spatial variation is critical to understanding the cell state but is challenging because the 
microenvironment is comprised of CQA biomarkers that are masked by other types of 
biomolecules in cell culture media. These biochemicals are necessary for culture health but 
are also present in high abundance in the bulk. This poses a hurdle for direct ESI-MS 
without any type of offline chromatographic separation, as direct analysis is more likely to 
detect only higher concentration biomolecules. While monitoring bulk media may be 
useful for detecting the downregulation of species like glucose or oxygen, the complete 
culture state is not captured by these measurements. Monitoring the local cell environment 
is therefore critical to understanding the underlying mechanisms or parameters that 
correlate with final therapeutic product quality, potency, efficacy, etc. 
This chapter explores the application of DSP to monitoring live cell cultures. First, DSP 
is applied to three human cell types to demonstrate the ability of the system to utilize 
localized sampling to generate unique fingerprints associated with each cell type. Next, a 
longitudinal study demonstrates that DSP can detect important aspects of cell state, such 
as proliferation, confluence, and differentiation. For these experiments DSP sampled 
directly from culture aseptically throughout the entire ~21 day growth cycle, validating the 
system’s capability for providing insight to cell state without affecting final product 
quality. Localized sampling from these cultures is shown to be required to detect cell state 
using post hoc analysis. Finally, a new workflow for enabling DSP as an orthogonal 
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approach to detect CQA biomolecules is presented, laying the groundwork for DSP as a 
discovery tool in cell manufacturing.  
4.1 Localized Sampling for Cell Fingerprinting 
Commonly used methods to characterize cell cultures or their conditioned media, for 
instance ELISA or HPLC-MS, analyze bulk samples. In the case of ELISA, the approach 
is highly sensitive and targeted, whereas HPLC is sensitive but mostly untargeted. In both 
cases the assay cannot pinpoint biomolecules’ point of origin nor identify the moment of 
secretion; the assays reveal spatially and temporally averaged CQA content. DSP seeks to 
address the shortcomings of these approaches by sampling directly from where the CQA 
biomolecules are secreted, i.e., the cell microenvironment adjacent to the cell membrane, 
and immediately processing the sample for real-time feedback.  
In order to maintain clinical relevance, DSP was first applied to three different types 
of human based cells. These cells were cultured with different medias and were from 
different source materials, thus they were expected to exhibit clear differences in the 
resulting DSP-MS spectra. First, DSP-MS analysis of a single normal human lung 
fibroblasts (NHLFs) cell culture was performed to compare bulk and local sampling effects 
with results presented in Figure 4.1. The first and third spectra are from a localized sample, 
taken ~100 μm above the cell membrane, while the second and fourth spectra are the result 
of bulk media analysis. The red boxes on the localized samples highlight spectral features 
that differ from bulk samples. The presence of highly resolved peaks in the local samples 
indicates that the cell microenvironment contains higher concentrations of biomolecules 
that are not detectable in bulk samples. For these experiments, no species identification 
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was carried out, as the Bruker MicroTOF MS is not capable of performing MS-MS analysis 
for  protein sequencing or database matching.  
DSP was then applied to two other cell groups, human mesenchymal stromal cells 
(MSCs) and human umbilical vein endothelial cells (HUVEC) to fingerprint each cell type 
 
Figure 4.1: Localized sampling (first and third spectra) from normal lung 
fibroblast cells (NHLF) reveals a drastically different spectra than those of bulk 
samples (second and fourth spectra) indicating that the region near the cell 
membrane contains biochemicals that become diluted below limit of detection in 
the bulk media. 
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with localized sampling. Figure 4.2 shows the resulting spectra for each cell group. Each 
spectra differs significantly; however, because each cell is phenotypically unique and the 
media used to culture the cells is different, it is not clear whether the qualitative differences 
in each spectra are due to secreted factors associated with cell type or due to bulk media 
composition differences. Nevertheless, the complex spectrum for each cell type is not 
dominated by a common signal, such as a frequently used serum additive like albumin. In 
the HUVEC spectra, some indication of heavy protein content is shown in the m/z 1200-
2000 range, but the fact that this signature it is not present in each spectra suggests that 
 
Figure 4.2: DSP application to three types of cell cultures with localized 
sampling demonstrates key ability to “fingerprint” different cell types.   
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local sampling mitigates the effects that high weight proteins found in additive serums, like 
albumin, have on detecting locally secreted CQA biomarkers.  
From a clinical perspective, MSCs have shown some promise for their anti-
inflammatory potential and their role in producing tissue engineered medical products for 
regenerative medicine.15, 62, 63 MSCs, like most stem cells, naturally differentiate into 
different phenotypes depending on their biological context. Whether in vivo or in vitro, 
determining MSC differentiation state is important for predicting the cell’s therapeutic 
potential. Therefore, predicting cell state at each developmental stage, from proliferation 
to confluence to differentiation, is a critical area for DSP application. To this end, an 
experiment was designed with a cell type with well understood differentiation properties, 
i.e., MC3T3 preosteoblasts. While MSCs, IPSCs, and T-cells may differentiate into a range 
of sub-types the MC3T3 cell type differentiates controllably from preosteoblast to 
osteoblast. Additionally, the assay used to detect differentiation is well documented and 
only two additives are used to induce differentiation, which enables more control over the 
cell growth cycle and reduces the sources of experimental noise that more complex cell 
types inherently possess.  
4.2 Cell Culture Method 
Murine preosteoblastic cells MC3T3-E1 (ATCC CRL-2593) were obtained and 
expanded according to established protocols.64 Gilad Doron (Guldberg/Temenoff lab) 
carried out all of the cell cultures as described here.  Cells were seeded on T-150 flasks 
(Corning) at 5000 cells/cm2 and expanded in a growth media consisting of MEM ⍺ with 
nucleosides (Gibco) with 10% fetal bovine serum (Atlanta Biologicals, Lot #E15052) and 
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1% penicillin/streptomycin (Corning). Media was replenished with clean growth media 
every 2-3 days until cells reached 80% confluence. Once confluent, cells were washed with 
phosphate-buffered saline (PBS, Gibco) and detached from flasks with 0.25% trypsin-
EDTA (Gibco). Dissociated cells were counted and replated onto 6-well plates at 5x105 per 
well (53,000 cells/cm2). After overnight adhesion, MC3T3s were separated into two 
groups, one group subjected to osteogenic differentiation (i.e., differentiated group) using 
the In Vitro Osteogenesis Assay Kit (ECM810, EMD Millipore) and the other cultured in 
growth media (i.e., undifferentiated group). For cells undergoing osteogenic 
differentiation, media was aspirated and replaced with 2.5 mL growth media supplemented 
with 0.2 mM ascorbic acid 2-phosphate (EMD Millipore), and 10 mM glycerol 2-
phosphate (EMD Millipore) while non-differentiated cells were aspirated and given 2.5 
Figure 4.3.  Representative images of the two cell culture groups after alazarin red 
staining A) In the undifferentiated group, which was not given additives to induce 
differentiation, no staining is evident B) In the differentiated group, red staining is 
seen throughout the culture indicating the presence of calcium deposits which are a 
byproduct of MC3T3-E1 differentiation. Image taken by Gilad Doron. 
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mL growth media with no additives. Every 3 days, media was replaced after DSP sampling. 
Immediately after sampling, conditioned media from both differentiated and non-
differentiated MC3T3s was aliquoted for layer analysis and replaced with their respective 
fresh media. After 6 days in culture, the differentiation media was also supplemented with 
50 nM melatonin (EMD Millipore). Both cell groups were cultured for 18 days total, being 
sampled 6 times total. After the final DSP experiment (day 18) cells were washed with 
PBS and fixed with 4% paraformaldehyde (Sigma Aldrich) in PBS at room temperature 
for 15 minutes. Fixative was removed and the cells were carefully rinsed three times with 
distilled water. Next, differentiated and non-differentiated MC3T3s were incubated in 2 
mL alizarin red staining solution (EMD Millipore) for 20 minutes. Staining solution was 
then removed and cells were washed 4 times with deionized water. Osteogenic 
differentiation was confirmed in the differentiated group by red staining of calcium 
deposition, while no staining was observed in the non-differentiated group, as shown in 
Figure 4.3 (photo credit: Gilad Doron).  
4.3 DSP Application to 2D Cell Culture 
The MC3T3 cells were cultured in the Guldberg/Temenoff lab (IBB) by Gilad 
Doron. The DSP and MS systems were located in the Fedorov lab (Love) approximately 
10 minutes walking from where the cells were cultured. Moreover, the Fedorov lab was 
not equipped with sterile space for culture manipulation (i.e., biosafety hoods) which 
increased the chance that the culture would become contaminated. To overcome these 
limitations, a method for sample transport and direct-from-culture sampling outside of a 
biosafety hood was developed. This protocol was designed to preserve the cell growth 
processes throughout the entire culturing period. When ready for sampling, the cells were 
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removed from the incubator and placed into a sterile fume hood. The 6 well plate cover 
was removed and replaced by autoclaved aluminum foil, which was taped down in a 
manner that allowed for visual inspection through the side of the culture plate. During 
sampling, a digital microscope was positioned orthogonally to the cell culture plate, 
allowing for visual confirmation of sampling mode (i.e., local or bulk) as shown in the 
Figure 4.4 inset images. After the cells were ready for transport, they were placed in a 
Styrofoam cooler and brought to the Fedorov lab, where they were immediately placed on 
a hotplate to maintain the media at ~37 °C throughout the entire sampling process for DSP-
ESI-MS analysis.  
 Direct from culture DSP-nanoESI-MS analysis was carried out every 3 days, 
immediately before media changes, allowing for the highest concentration of biomolecules 
to be secreted between time points. The MS was tuned and calibrated using BrukerTM tune 
mix at the start of each experiment to facilitate accurate mass identification. To remove all 
air bubbles, which interfere with continuous ESI, the entire sampling interface and DSP 
system was primed with sterilized DI water. To allow access to the cell media through the 
aluminum foil a 22 gauge sterilized hypodermic needle was used to puncture the foil and 
the sampling inlet was inserted through the hole. Directly before each sampling event, 2 μL 
of the sterilized water was pumped out of the sampling inlet at 100 μL/hr to purge the 
sample inlet line, reducing sample carry over effects. Samples of 1 μL volume were drawn 
into the sampling interface at 50 μL/hr and subsequently infused through the DSP for direct 
ESI-MS analysis at 30 μL/hr. Conditioning flow (1% acetic acid, 1% m-NBA) was run 
continuously at 50 mL/hr in crossflow orientation throughout the entire experiment. The 
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conditioning flow channel also served as the electrical connection for a picoammeter, 
which was connected to a stainless-steel wire submerged in the conditioning liquid 
reservoir. The electrospray current during all experiments was maintained at 10-20 nA so 
that the ESI characteristics remained consistent between experiments. Between each 
Figure 4.4.  Dynamic Sampling Platform (DSP) setup for direct 2D cell culture 
analysis. The DSP, in the fluidic package, is positioned so that the ESI emitter is 
directly in front of the MS inlet. The DSP is connected to the sampling interface, 
which consists of a 50 μL syringe, union, and sampling inlet. Localized sampling is 
carried out by positioning the inlet directly above the bottom of the cell culture, in 
close proximity to the cells, while bulk sampling is carried out by submerging the 
capillary just below the media surface (inset images).  
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sample, DI water was infused through the DSP and into the MS via ESI to remove residual 
media from the fluidic system and to reduce MS signal carryover before starting another 
sampling event. A total of 6 samples were captured from each cell group (i.e., 
differentiated/undifferentiated) at each time point. At each sampling event, 3 local and 3 
bulk (Figure 4.4, inset) samples were taken with each sample taken at a spatially disparate 
locations to probe heterogeneities throughout the volume.  
The resulting spectra from DSP application to the MC3T3 cell cultures (Figure 4.5) 
are not distinguishable without careful analysis. To analyze this data, principal component 
analysis (PCA) was used. PCA is an unbiased approach to data analysis that was used to 
identify features in the data which are hypothesized to correspond with known cell states. 
Raw data from the first and last time points is shown in Figure 4.5. Note that most of the 
salient signal is in lower m/z ranges which was confirmed to contain the features most 
Figure 4.5 Raw data from the first and last timepoint for both cell groups. No 
clear differences are observed between the data, necessitating the use of an 
unbiased data analysis to identify features indicative of cell state. 
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indicative of cell state. Preprocessing of the resulting spectra, mostly in the form of 
smoothing and winnowing, was used to tease out features in the large (72 spectra total) 
data set that contributed to differences between the groups.  
4.4 Raw Data Preprocessing  
Bruker MicrOTOF output files gathered for each of the 72 samples were parsed and 
converted to “mzML” file type using the open source data conversion software, 
ProteoWizard.65, 66  Principal component analysis (PCA) was completed using two open 
source software utilities. The first was ms-alone, a python-based utility for preprocessing 
and peak extraction used on the raw mzML files prior to importing the data to the second 
utility, multiMS-toolbox, an R based software for PCA analysis.67 Preprocessing was 
accomplished using ms-alone on the raw data including baseline subtraction and peak 
smoothing. Within ms-alone, the signal to noise ratio threshold of data was set to 0.5, and 
a Savitzky-Golay smoothing method was used to reduce noise.68 The parameters used for 
these steps of pre-processing were recommended by the developers and implemented to 
enable data transfer between the different software utilities. The final PCA results did not 
depend on these steps, but the results did depend heavily on the winnowed range of m/z 
values used for comparing the time points.  
PCA is used for a range of applications, but for the DSP results it was used to 
determine if differences between the cells in their different differentiation states are 
reflected in the spectra. Therefore, the input to the PCA was the entire spectra and the 
outputs are principal components and associated “loadings” which reveal which features 
in the spectra that contribute most to differences between the groups. Each principal 
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component has a percentage value assigned to it and a loading plot associated with it. The 
loading plots are simply reconstructed spectra comprised of m/z values and contribution to 
variance. Therefore, principal components with high percentage values assigned to them 
are more likely to have spectral features in the loading plots that correspond to actual 
differences between the raw spectra. 
Before conducting PCA, each data point was tagged with properties such as time 
point, differentiation status, and whether it was a bulk or local sample. An entire spectra is 
represented as a single point on the output PCA scatter plots. The PCA protocol groups the 
data based on how similar the input data is. PCA is unsupervised, and therefore groups data 
based on their principal component loadings which are assumed to be due to the tagged 
properties, but unlike other supervised methods, PCA does not force the separation of 
Figure 4.6: Resulting PCA scatter plot for unwinnowed data from 
localized sampling done on cells in their undifferentiated (red dots) 
and differentiated (green dots) states. The lack of separation 
between the different colored points indicates there is no consistent 
difference between the two groups. 
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groups based on these tags. When the different groups separate well, this indicates that 
there is a variable responsible for this difference that may not be directly measured, which 
in this case was cell state. A large swath of each spectra had low intensity signal, and this 
reduced the effectiveness of PCA in revealing differences between the data sets. Therefore, 
the spectra were winnowed prior to the final analysis. To demonstrate the effect that 
winnowing had on PCA results in this chapter, a sample workflow is presented here.  
First, intensity based (i.e., no data normalization) PCA was run on the entire spectrum 
(m/z 0-2500) of cells in an undifferentiated and differentiated state. To increase the count 
of data points in each group, multiple points were grouped such that each group (e.g., 
undifferentiated, differentiated, proliferative, etc.) had at least 6 spectra to represent it. The 
specific groupings, and the reasoning behind them, are discussed in detail in section 4.5. 
The data used for this demonstration is for the local samples taken from time points 5 and 
Figure 4.7: Loading plots for PCA in Figure 4.6: reveals a large 
part of the input spectra does not contribute to variance between 
the groups. A threshold value of 20% of the maximum was used to 
winnow the data. 
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6 from the differentiated and undifferentiated groups. The green dots represent cells which 
were differentiated, while the red dots represent cells that maintained their undifferentiated 
state. Without any data winnowing, the groups do not show any separation (Figure 4.6:). 
This suggests that there is no significant difference, based on the input spectra, between 
the groups. However, in the loading plots that correspond to these two principal 
components there are areas of the spectrum that appear to have more contribution to the 
variance than others. These regions are highlighted in the red boxes in Figure 4.7. 
Selecting a threshold value in the loading plot, which was 20% of the absolute value 
of maximum/minimum, the data was winnowed to remove the low contribution features in 
higher m/z ranges (above ~1000 m/z in this case). PCA was again run on the winnowed 
Figure 4.8: PCA on the same data shown in Figure 4.6: with the 
winnowing approach from Figure 4.7 reveals two groups 
corresponding to undifferentiated (red dots) and differentiated 
(green dots) cells. Discussion of data detail is in Section 4.5. 
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data, and the resulting PCA scatter plot in Figure 4.8 shows two groupings corresponding 
to the known difference in the sampled media, which was differentiation state.  
4.5 Detecting Cell State 
The ability to determine, in real-time, cells’ health, therapeutic potential, or 
developmental state is paramount to developing effective feedback control for cellular 
therapy production (e.g. immunotherapies, biologics, regenerative medicines). Whether or 
not a cell has differentiated is an important aspect of the cell’s state. For example, clinically 
relevant cells such as mesenchymal stromal cells (MSCs) have their therapeutic potential 
drastically altered depending on their differentiation state.69, 70 As a first step towards real-
time monitoring of primary cell cultures, DSP was applied to MC3T3 cells for rapid ESI-
MS, followed by PCA of the collected spectra to determine if features in the raw spectra 
corresponded to differences in the secretome, and therefore the cell state.  
 The MC3T3 cells used in this study served as a proxy to clinically relevant cells 
due to their predictable differentiation behavior, with a developmental sequence similar to 
osteoblasts in bone tissue.71 As cells grow and differentiate, the molecules they secrete 
have the highest concentration near the cell membrane, while the concentration of these 
secreted biomolecules in the bulk media grows slowly with time due to substantial dilution. 
Therefore, these experiments were designed so that sampling was done just before media 
changes, when the biomolecules would be at the highest concentration in the bulk media, 
to investigate if localized sampling provides a different analytical outcome than bulk 
sampling. At each of the six time points triplicate samples of bulk and local (Figure 4.4, 
inset) were taken for both cell groups (i.e., differentiated and undifferentiated).  
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 Representative data from the first and last time point for both the undifferentiated 
and differentiated cell groups is shown in Figure 4.5. As discussed, detecting any 
differences in the spectral data required statistical analysis. The data processing approach 
outlined in section 4.4 enabled PCA to identify differences between the spectra and to 
identify m/z values that contribute most to variance between data. These selected m/z 
values were then later used to for comparison with offline high performance liquid 
chromatography (HPLC) data.  
 Due to the small number of sample replicates at each time point, data from multiple 
time points were grouped to increase the robustness of PCA. For each time point, PCA is 
carried out on bulk and local samples to study localized sampling enrichment. Figure 4.9 
shows the resulting PCA scatter plots for bulk samples taken from time points 5 and 6 
grouped together for the undifferentiated and differentiated groups. These are the last two 
time points measured using DSP with direct ESI-MS analysis. The cells in the 
differentiated group are expected to have begun differentiation by time point 4 and 
completed by time point 5, while the cells in the undifferentiated group remained 
undifferentiated throughout the experiment. Time points 5 and 6 were therefore grouped to 
represent the cells in their fully undifferentiated or differentiated state, respectively, and to 
omit earlier time points where the cells were still expanding or undergoing the 
differentiation process. Subsequent staining in Figure 4.3 of both the undifferentiated and 
differentiated cell lines confirmed that the cells had either remained in the undifferentiated 
state or had completed differentiation after time point 6.   
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The clusters in the PCA plot based on bulk sampling in Figure 4.9 are not well 
segregated, which suggests that there is no significant difference in the spectra in the bulk 
sampling case. Localized sampling, on the other hand, reveals a strong clustering of the 
two groups, shown in Figure 4.10. This indicates that localized sampling is important for 
the detection of differences in cell differentiation state. Both cell groups were given 
different media throughout the culture process, but these differences are not revealed by 
the bulk samples which suggests that the differences observed in the local samples are due 
to secreted biomarkers captured near the cells, and not due to differences in the cell culture 
media composition. Additionally, the DSP selectively removes smaller molecules from 
Figure 4.9: Principal component analysis (PCA) cluster plots for bulk samples taken 
from time points 5 and 6 of the undifferentiated cell group vs time points 5 and 6 of 
the differentiated cell group reveals no clustering. 
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treated samples while retaining larger biomolecules. The additives given to the 
differentiated cell group have molecular weights below 300 g/mol (Da), and were likely 
removed during DSP treatment 72 .  
Figure 4.10: Principal component analysis (PCA) cluster plots for local 
samples taken at time points 5 and 6 of the undifferentiated cell group vs 
time points 5 and 6 of the differentiated cell group. Localized sampling 
reveals clusters for the two groups, indicating that localized sampling 
captures the cells’ differentiation state. 
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 In order to observe if the same cell culture exhibited differences with time, and to 
remove the contribution of cell culture conditions to the variance in data, the same 
differentiated cell culture, i.e., the culture given the osteogenic factors to induce 
differentiation, was analyzed alone. Time points 1 and 2 were grouped and compared to 
time points 5 and 6. These groupings compare the cells in early time points, when they 
Figure 4.11: Principal component analysis (PCA) cluster plots for bulk samples 
taken from the differentiated cell line at time points 1 and 2 versus time points 5 and 
6. Cells were expected to begin differentiation between time points 3 and 4, with 
differentiation completed by time point 5. Bulk sampling does not exhibit any 
clustering. 
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have not completed differentiation, to the cells in a fully differentiated state. Because all of 
the data was taken from the same cell culture in the same continuously performed cell 
growth and development experiment, this approach also removes the possibility that 
Figure 4.12 Principal component analysis (PCA) cluster plots for local samples taken 
from the differentiated cell line at time points 1 and 2 versus time points 5 and 6. 
Cells were expected to begin differentiation between time points 3 and 4, with 
differentiation completed by time point 5. With localized sampling, clusters are 
observed indicating that DSP detects differences between undifferentiated and 
differentiated cell lines by probing the near cell enriched secretome. 
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different culture conditions (e.g., seeding density, media type, etc.) contributed to the 
differences observed.  
Figure 4.11 shows the resulting PCA plots for bulk samples taken from the 
differentiated cell group at early and late time points. Once again, the spectra do not exhibit 
significant clustering for bulk sampling, which suggests that the spectra do not contain 
features contributing to differences between groups. Figure 4.12 shows that again localized 
sampling is paramount for detecting cell state. In these cluster plots, the early and late stage 
groupings correlate with cell differentiation status. The top cluster plot in Figure 4.12 also 
exhibits clear subgroup separation between the early stage cells represented by red boxes, 
which was confirmed to correspond with time point 1 and time point 2. This suggests that 
not only does localized sampling capture clear differences in cell types, such as whether or 
not they have differentiated, but also more subtle aspects of cell state, e.g., whether the 
cells are in a proliferative or confluent states.  
PCA was performed as previously described (i.e., time points 1 and 2 vs time points 
5 and 6) for the data from the undifferentiated cell group. In this case, bulk sampling once 
again resulted in no separation (Figure 4.13) and for local sampling (Figure 4.14) the 
separation between the two groups is not obvious, though some grouping is evident. The 
localized sampling data suggests some changes in the undifferentiated cells with time. 
Staining at the end of the experiment (Figure 4.3) confirmed that this group remained in an 
undifferentiated state, and therefore these differences are not due to differentiation. One 
possible explanation is that the differences observed are due to a change in the cell 
secretome during expansion, which has been shown to correlate with preosteoblasts in a 
state of proliferation (early) or confluence (late).73 Another possibility is that the cells 
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underwent another phenotypical change, such as apoptosis. Further studies will explore 
DSP determination of cell secretome correspondence to cellular state, from early 
Figure 4.13: Principal component analysis (PCA) of  bulk samples taken from the 
undifferentiated cell group at time points 1 and 2 versus 5 and 6. Bulk sampling 
shows no separation between groups. 
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proliferation, later confluence, and in certain cases final differentiation. Once biomarkers 
are correlated with cell state, DSP will provide the unprecedented ability to monitor cells 
Figure 4.14: Principal component analysis (PCA) of  bulk samples taken from the 
undifferentiated cell group at time points 1 and 2 versus 5 and 6. Local sampling 
reveals moderate separation, indicating a difference between the groups such as 
proliferative (early time point) vs confluent (late time point). 
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in real-time. This approach will enable improved quality assurance and reduced batch-to-
batch variability with closed-loop feedback control.  
To enhance biochemical interpretation of the PCA analysis, offline HPLC-MS was 
performed on aliquots of conditioned media which were gathered during media change and 
frozen at -40  ͦC until the end of the study. HPLC was carried out on media from both cell 
types at time points 1, 2, 5, and 6 to identify candidate differentiation biomarkers and to 
quantify differences in biomolecules between time points. The candidate biomolecules 
identified with HPLC were then manually compared to m/z values with the highest 
contribution to variance in the PCA data that are hypothesized to correlate with cell state 
(i.e., differentiated vs undifferentiated). The mass spectrometer used for direct-from-
culture DSP analysis was not equipped with tandem mass spectrometry (MS-MS) 
capability, therefore fragmentation patterns could not be matched to the HPLC-MS data. 
As a result, the m/z values from the PCA loading data were matched to potential chemicals 
from HPLC-MS based on accurate mass alone, resulting in tentative IDs only. A large 
number of candidate molecules were identified using this approach, but only those which 
Table 4.1: List of potential chemicals identities based on HPLC matches 
to DSP-MS based PCA loading plots. 
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had been cited in literature are presented in Table 4.1.71, 74-79 These results demonstrate that 
DSP serves to not only generate cell culture “fingerprint” spectra, but to also identify which 
detected biomolecules correlate with cell state. For more complete identification of 
biomolecules, DSP can be used with MSn for fragmentation to generate candidate IDs 
before HPLC is carried out. Further studies will elucidate the manner in which PCA loading 
data correlates with HPLC-MS data for independent identification of CQA biomarkers 
using DSP based analysis. Integrating DSP directly into workflows with MS instruments 
with tandem MS capabilities will also ensure that instrument-to-instrument variability is 




CHAPTER 5.  
CONCLUSIONS AND FUTURE WORK 
The Dynamic Sampling Platform (DSP) is a new technology for real-time quality 
monitoring and CQA discovery for biomanufacturing. This thesis focuses on DSP 
development and applications in the growing field of cellular based therapies, which 
include immunotherapies such as the CAR-T cell treatment, regenerative medicines, and 
other promising therapeutics for previously untreatable ailments. DSP is designed as a 
drop-in sensor with broad applicability. Therefore, well established biomanufacturing 
industries can also adopt the DSP enabled analytical capabilities, including the biologics 
field which would benefit from the ability to characterize large and complex proteins in 
their native state.4, 5, 18, 38, 80, 81 The DSP is capable of probing bioreactors with high spatial 
and temporal resolution to capture the transient and spatial heterogeneities which correlate 
with cell state and therapeutic potential. These secreted biomolecules are in high 
concentration near where the cells are located, so the ability to capture the CQA biomarkers 
where they are produced unlocks a new method for quality monitoring in 
biomanufacturing. Importantly, DSP will provide real-time feedback on the cell state based 
on its secretome evolution, a current void in process analytical technologies (PATs) that is 
considered as the primary bottleneck for bringing promising advanced therapies to a wide 
patient population.6  
In CHAPTER 2, the fully integrated DSP PAT for integration with good manufacturing 
practice (GMP) workflows is presented. For clinical applications, especially GMP 
workflows, the cell bioreactor, DSP, and mass spectrometer are expected to be spatially 
separated which confounds the application of the DSP sensor system to advanced 
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workflows. To overcome these barriers, the DSP is designed to couple with a novel sample 
uptake system, the dynamic sampling interface (DSI), and an ion transfer interface for 
analyte transport. The DSI is a minimally invasive sampling technology for direct from 
culture sampling with minimal loss of sensitivity due to sample dispersion effects. Central 
to the DSP technology is the microfabricated mass exchanger which is produced in a 
scalable format. The microfabrication approach is used for precise feature size control that 
enables DSP’s inline sample treatment. A novel clog-resistant counterbore inlet/outlet 
geometry allows monolithic integration of the sampling interface and an ESI outlet. For 
application to GMP workflows, the sampling interface, mass exchanger, and ESI outlet are 
positioned near the cell culture, while an ion transfer interface couples the MS instrument 
to the DSP for real-time analysis.  The ion transfer interface is introduced for the transfer 
of analyte ions in gas phase over many meter distance from the DSP system to the mass 
spectrometer without significant loss in signal. Importantly, the fully integrated system is 
capable of maintaining sterility and minimally disturbing the cell culture. Finally, an 
optimization study for the DSP mass exchanger is presented, and a simple change in device 
mass exchanger operation from counterflow to crossflow orientation improves device 
efficiency. This improved design is critical for enabling clinical workflows where the 
sample treatment requirements are burdensome such as those explored in CHAPTER 4. 
CHAPTER 3 demonstrates that the DSP active sample conditioning approach enables 
a broad range of CQA biomolecule detection. During sample treatment, a size selective 
membrane allows for the transport of interfering species (salt) out of the sample and the 
infusion of signal enhancing chemicals into the sample. A reduced effective diffusion 
coefficient for larger biomolecules enhances the retention of CQAs in the sample while 
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effectively removing small (high diffusion coefficient) salt molecules through the 
nanoscale pores of a dialytic membrane, enabling real-time ESI-MS with improved 
sensitivity. Active sample conditioning is shown to enhance MS performance, including 
improved limit of detection, multi-component detection, and increased dynamic range for 
high molecular weight biomolecule detection. The experiments presented in this chapter 
serve as proxies to clinically relevant testbeds and demonstrated the DSP’s capability for 
real-time ESI-MS bioreactor monitoring.  
Application of DSP to living cell cultures demonstrated the key capability to detect cell 
state during the cell development trajectory in CHAPTER 4. First, comparing local and 
bulk samples from NHLF cells revealed a biochemical signature in the microenvironment 
that was qualitatively different from bulk samples, suggesting the need for localized 
sampling to detect cell state. Two other clinically relevant cells (MSCs, HUVECs) were 
compared to the local NHLF samples for cell-type fingerprinting, demonstrating DSP’s 
key ability to detect cell state. To detect more subtle aspects of cell states, such as 
differentiation, a longitudinal study was carried out on preosteoblast MC3T3-E1 cells. DSP 
was applied to cells throughout their entire cycle without affecting culture sterility or final 
cell state. Post hoc analysis of the 21 day study revealed that localized sampling was 
paramount to detecting cells in their proliferative, confluent, undifferentiated, and 
differentiated states. Using PCA as an input, orthogonal HPLC analysis was used to 
identify potential CQA biomolecules, establishing the workflow for DSP as not only a 
spectral fingerprint monitoring tool, but as a tool for detailed discovery of critical process 
parameters and unambiguous molecular identification of cell state predictors.  
5.1 Original Contributions  
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This PhD research made several important contributions to fundamental science and 
to the engineering practice as stated next. 
Fundamental Science 
1. A new analytical concept (DSP – Dynamic Sampling Platform) for process 
monitoring of bioreactors has been introduced, including the key enabling 
technology components and an integration approach for applications in 
emerging cell therapy development. The core element of the DSP is the 
microfluidic mass exchanger that was developed using new design and 
microfabrication approaches, which ultimately led to significant analytical 
advances. Using a combination of active sample conditioning including 
dialytic salt removal, sample acidification, and chemical conditioning via 
supercharging molecules the DSP micro-mass exchanger i) improves ESI-
MS sensitivity to low concentration biomolecules by an order of magnitude 
in samples with high salt content, ii) enables multicomponent detection of 
protein biomarkers of significance to cell therapy quality and potency 
assessment, and iii) expands the mass range for high molecular weight protein 
detection through the use of carefully optimized sample conditioner. These 
results prove that DSP active sample conditioning fundamentally improves 
ESI-MS analysis due to several chemical mechanisms (e.g., supercharging, 
acidification, protein conformation) that previously were unexplored in real-
time applications.  
2. DSP provides a pioneering methodology for in situ probing of the rich 
biochemical microenvironment in cell bioreactors locally, in a transient 
 106 
manner. Samples taken directly from bioreactors with subsequent DSP active 
sample conditioning and inline ESI-MS measurement are shown to correlate 
directly with cell state. A longitudinal study of living cells demonstrates that 
the DSP’s ability to detect cell proliferation, confluence, and differentiation 
are enhanced by localized sampling and active conditioning.  
3. DSP enables a novel approach to statistically significant correlation of 
dynamically acquired MS spectral signature of secreted CQA biomolecules 
(molecular fingerprinting) with the cell biochemical state. When used in 
combination with HPLC-MS as a complimentary offline identification 
approach, it establishes DSP as a powerful biosensing technology for both 
real-time process monitoring and new therapy discovery applications in 
biomanufacturing.  
Engineering Practice 
1. Development of a scalable, transferable microfabrication process for a 
microfluidic ESI-MS platform technology based on a micro-mass exchanger 
with integrated sampling and electrospray ionization capabilities. Design 
rules for enhanced mass transfer in counterflow and crossflow orientations of 
the mass exchanger have been identified and used to achieve an enhanced 
analytical performance.  
2. Demonstration and optimization of a sterile sampling method for direct-from-
culture sampling with the dynamic sampling interface (DSI) for isolated 
sample uptake and infusion capabilities; design rules for mitigating the 
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detection sensitivity penalty due to dispersion during sampling/sample 
transport to MS analysis. 
3. System level integration of a long distance gas-phase ion transfer interface 
with the DSP platform and mass spectrometer to enable real-time quality 
monitoring of cell bioreactors in GMP facilities, where cell culture and 
analysis must take place in physically separated locales. 
5.2 Research Areas for Future Work 
With the advances made in this dissertation research, DSP was advanced to the 
market readiness level (MRL) 4-5 for application to biomanufacturing workflows, but 
additional studies will aid improving DSP performance in application to salient testbeds. 
The size selective membrane, which is monolithically integrated into the DSP mass 
exchanger, has an average pore size of approximately 50 nm. The effective diffusion 
coefficient of a biomolecule in a small pore is inversely proportional to the ratio of the 
molecule diameter to the pore diameter, so therefore decreasing the size of pores improves 
the retention of smaller molecular weight biomarkers in the sample.82 DSP’s effectiveness 
at removing/retaining a specific molecule is a function of the molecule’s effective diffusion 
coefficient through the nanoporous membrane, which is shown in Figure 5.1. Three graphs 
show the effect of reducing pore size on selectivity of separation of different molecular 
weight compounds. Currently, at the 50 nm pore size, DSP effectively removes ~70% of 
the IL-8 content, which explains why this molecule was not visible during active sample 
treatment in section 3.4. By reducing the pore size to 15 nm, or even lower to 6 nm, DSP 
should remove approximately 50% or 10% of the IL-8 content; this improved selectivity 
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will enable DSP to detect smaller signaling molecules with little detrimental effect on the 
removal of small salt ions, as DSP’s effectiveness at removing very small salt ions is nearly 
independent of pore size. 
Some work was done to reduce the pore size by changing the electrolyte from oxalic 
acid to sulfuric acid and changing anodization potential during the Al2O3 fabrication, which 
was observed to reduce pore size to approximately 10 nm. These devices did not remove 
salts, which is thought to be due to incomplete anodization, residual barrier layers, or 
Figure 5.1: DSP is less effective at removing larger biomolecules with a 
reduction in nanoporous membrane pore size. The current DSP system has 50 
nm pores, and reducing the pore size further would increase DSP selectivity to 
larger CQA biomolecules.  
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unexpected tortuosity within the porous structure that increased mass transfer resistance. 
By reducing the pore size far below the 10 nm level, the mass transfer resistance across the 
membrane may increase significantly. This will increase the time necessary to remove the 
same amount of interfering salt ions, which may be of some concern depending on the 
application. Alternative designs can reduce characteristic lengths in all areas of mass 
transfer to improve the performance, i.e., reducing sample channel height, membrane 
thickness, and conditioner channel height.  
Retaining molecules with weights below ~15 kDa is of interest because the signaling 
molecules that correlate with cell state are in this mass range. On the other hand, larger 
molecules like albumin, which are in very high abundance in cell media, are retained very 
effectively. The presence of these heavy proteins will dominate the MS spectra masking 
other important analytes. For some workflows, such as those involving biologics or 
monoclonal antibodies, this may be desirable, but in initial experiments with bulk 
monitoring of low concentration additives in some types of cell culture media it was found 
Figure 5.2: Inline filter for high MW cutoff based on prior designs by Olivero et. al. 
Two separate output flows will allow for parallel analysis (via DSP) of effluent with 
high MW content and low MW content. 
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that signal from serum albumin overwhelms the spectra. In cell culture media, serum is 
orders of magnitude higher in concentration than CQA biomolecules, and accordingly 
serum masks the signal of most biomarkers. Therefore, additional separators may be placed 
inline with DSP to serve as a low molecular weight pass filter. One possibility is to design 
a continuous inline filter, similar to the one used by Olivero et. al, to separate raw cell 
culture media into high MW and low MW streams.33 Other possibilities are inline 
digestion, precipitation, or modified chromatographic columns for selective removal of 
larger proteins. 
Coupling DSP to clinical workflows that take place within GMP regulated facilities 
requires careful design of the interfacing components, namely, the DSI and the ion transfer 
interface. For adherent, 2D cell cultures that are common in research settings, obtaining 
minimally invasive samples intermittently was easily accomplished with the iteration of 
DSI presented in CHAPTER 2. Producing cells at scale necessitates the use of bioreactors. 
These bioreactors may be fed batch, stirred tank, cell stacks, or other geometries that are 
not amenable to direct sampling. Therefore, an effective sampling interface should be able 
to extract sample from these complex bioreactors without affecting culture sterility or 
bioreactor function. For example, coupling DSP with an N-degree of freedom “snake” 
robot for highly resolved inlet manipulation can enable DSP to probe the spatial and 
temporal heterogeneities within commercially relevant bioreactors. Alternatively, 
designing the bioreactors to allow for one-way sample uptake (e.g., a check valve sampling 
port) is another approach for DSI integration. In addition to sampling concerns, 
transporting the sample from DSP to analysis is a critical area for DSP improvement.  
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The ion transfer interface presented in CHAPTER 2 was based on prior art by 
Garimella et al. This system was shown, in agreement with literature, to reduce sensitivity 
and to preferentially transmit lower charge state ions.42 Optimizing the transfer interface 
such that it does not hinder the DSP approach to bioreactor monitoring is a critical area of 
further research. Exploring positive pressure systems, i.e., higher pressure at the ion 
transfer inlet vs MS inlet, will allow for higher flow rate operation. It was reported that 
ions are generally transmitted more effectively at higher flow rates in larger diameter 
transfer tubes, but in fully turbulent regimes it is expected that enhanced mixing would 
lead to loss of ions due to wall collisions. Additionally, a large portion of the ion loss comes 
in the first meter of transmission. The counter electrode geometry presumably affects ion 
trajectory, as does the entry region to the interface where flow is developing 
hydrodynamically. Therefore, a holistic approach to the ion transfer interface should study 
the interplay between inertial forces, viscous forces, and space charge effects on ion 
transmission efficiency.  
Relevant testbeds for exploration with DSP should mirror clinically relevant areas of 
interest. Two immediate test beds are the concentration gradients in T-cell cultures and the 
transient nature of MSC cultures. The first FDA approved cell-based therapy, CAR-T cell 
therapy, has over 50% of the production cost tied up in materials and supplies alone. With 
price tags of single therapy dose well over $0.5M, the burden of material costs is 
substantial.80 IL-2 is added during production in high abundance, from 1 to 100 U/mL, and 
then left unmonitored. As the production scale increases, the spatial heterogeneities that 
exist in research grade bioreactors are likely exacerbated on larger scales. DSP can probe 
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local and bulk concentrations of additives, such as IL-2, and also monitor the transient 
secretion of IL-15, which is known to indicate cell subtype.38 
MSCs have yet to reach clinical relevance, although it is known that they secrete a 
number of anti-inflammatory signaling molecules as well as growth factors associated with 
angiogenesis. A common method used to prime MSCs is the addition of interferon-gamma 
(INFγ) or tumor necrosis factor alpha (TNFα).39, 83 The transient behavior of MSCs after 
priming, as well as the molecules which are released at different levels of priming, are both 
important research questions which will help unlock the therapeutic potential of these 
promising cell types. MSC and T-cell therapies are just a very small subset of the range of 
applications that DSP will prove useful both as a CMC (Chemistry/Manufacturing/Control) 
tool for biochemical mechanism discovery and product manufacturing monitoring and 
validation.  
As a platform technology, DSP can also be modified to couple with other sensing 
techniques. Mass spectrometry has advantages in being label free and highly sensitive, but 
it is also highly dependent on sample preparation and a relatively costly analysis method. 
Exploring other sensing techniques in conjunction with DSP, especially very fast and 
readily available methods such FTIR, Raman, and NMR, which also require a special care 
of sample treatment for improved selectivity and sensitivity of detection, will enable new 





APPENDIX A. DEVICE MICROFABRICATION  
This appendix provides specific details microfabrication process used to create the DSP 
mass exchanger. This was developed using instruments within the shared user GT 
cleanroom facilities and therefore the specific parameters may vary depending on the 
instrument condition.  
A.1 Detailed Microfabrication Workflow 
The purpose of this section is to outline in detail each fabrication step and provide 
insight as well as options for producing the DSP. In general, having the ability to transition 
between instruments can be helpful when navigating scheduling and maintenance issues in 
a shared-user facility, so multiple options are presented where they were found to work. 
Since the entire process relies on photolithography alignment, and eventually wafer level 
alignment, it is important to make sure the alignment mark system utilized will function on 
every instrument used. As a last note, the entire fabrication process should be walked 
through with an experienced user/staff member since there are compliance issue with 
certain instruments and some of the processes pushed the limits of the instruments.  
A.1.1 Wafer Selection and Preparation (A1, B1) 
The material properties of the starting silicon wafers do not affect the fabrication 
steps or final device performance, so double-side polished silicon wafers with any 
crystalline orientation and doping would function as the feedstock material for DSP, as 
long as the structural integrity of the device is maintained. With the specific workflow 
developed in the GT facilities, wafer alignment relied on IR microscopy and necessitated 
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that the wafers have IR transparency and be polished on both sides. Therefore, wafers with 
a resistivity of at least 0.05 ohm-cm were used, although any double-side polished silicon 
wafer should be adequate so long as alignment does not rely on IR transparency, for 
instance if external alignment marks with optical cameras are used. Wafers were acquired 
from Polishing Corp of America (PCA) that were 100 mm diameter, <100> orientation, 
double-side polished, 500 μm thick +/- 20 μm, p-type doped (boron), with resistivity 
between 1-20 ohm-cm.  
The first step of process flows A and B (Figure 2.13 and Figure 2.14) is thermal 
oxidation. Before oxidizing, the wafers underwent a standard CMOS piranha etch in 
batches of 25 wafers with a common use wet bench. Before beginning the etch, wafers 
were transferred into a Teflon wafer cassette for material compatibility with Piranha. The 
bath used for this cleaning step was initially filled with 3 liters of 98% H2SO4 (sulfuric 
acid) and each time the common use bath was used 100 mL of 60% H2O2 (hydrogen 
peroxide) was added, which means that the exact composition of the bath varied, but the 
resulting cleans were observed to be highly repeatable assuming the wet bench was 
operated per established protocols. The batch of wafers were placed in the bath before 
heating the bath to 120 °C, at which point the wafers were left in for a minimum of 10 
minutes. After the bath, the wafer cassette was removed and rinsed in the quick-dump 
rinser contained within the CMOS wet bench. This rinse process sprayed DI H2O on top 
of the wafer cassette until the tops of each wafer were submerged, followed by a quick 
dump of the bath; this fill/drain cycle completed five times. After rinsing, the wafers were 
placed in the spin rinse drier with the H-bar of the wafer cassette oriented inward and the 
standard cycle was used to again rinse the wafers before finally drying them by rapidly 
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spinning the cassette and blowing N2 across the wafers. At this stage, visual inspection of 
the wafers was carried out to confirm that no solid or liquid particles were left behind and 
that the polished surfaces of the wafers were free of imperfections. If any splotches, liquid 
pools, or solid particles were observed the entire cleaning process was repeated. Any 
imperfections at this stage affected oxidation of the wafer surface, and therefore the entire 
DSP fabrication flow was compromised by imperfections at this stage. 
Immediately after cleaning and inspection, each wafer was transferred from the 
Teflon cassette to a quartz cassette using a plastic vacuum “wand” wafer holder to avoid 
scratching the surface of the wafers. Wafers were oxidized at 1100 °C for 18 hours and 45 
minutes in a TystarTM Mini furnace in a wet oxidation environment, resulting in an ~3 μm 
thick layer of SiO2 that was confirmed with reflectometry. Final thickness of the SiO2 is 
not critical from a device performance perspective, but uniformity and the lack of pinhole 
defects is important to prevent bulk Si etching in later steps. The presence of pinholes 
resulted in inadvertent through etches during deep-reactive ion etching (DRIE). The 
presence of pinholes caused final device fracture or leaking while nonuniformity changed 
etch rates for plasma based reactive ion etch (RIE) steps across the wafer, leading to device-
to-device variation due to incomplete etching of key features. Additionally, variations in 
thickness can affect surface reflectivity and absorptivity that will change photolithographic 
dosage requirements that must be accounted for. Although SPR 220 was found to perform 
properly regardless of SiO2 film quality, the SU-8 3005 layer that served as the adhesion 
layer for the DSP was observed to be highly sensitive to any changes in substrate properties. 
A.1.2 SPR 220 Lithography and AMI Cleaning (A2, A4, B2)  
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MegapositTM SPR 220 is a positive photoresist with a thickness range of 1-10 μm 
with sensitivity to 405 nm wavelength. It was found to have excellent selectivity for both 
Si and SiO2 during etch steps and is easily removed with acetone or piranha. In the DSP 
workflow, care was taken to position any SPR 220 developing steps before aluminum was 
deposited since the developer used for SPR 220 (MF-319) etches aluminum, which can 
affect the aluminum film quality before anodization and induce delamination of Al2O3 after 
anodization.  
 Before spin coating SPR 220 the substrate was cleaned with a standard acetone, 
methanol, isopropyl alcohol (IPA) rinse. Both sides of the wafer were rinsed for 5 seconds 
with each solvent (first acetone, then methanol, then IPA) followed by  N2 drying of the 
surface not to be patterned by holding the wafer at an angle above a low particle count 
towel/wipe until visually dry before placing the wafer patterned side up on a low-particle 
count wipe, blowing N2 directly into the wafer, and moving in circular patterns from the 
inside to the outside to ensure that the side to patterned is completely dry without any 
splotches or solid particles. The consecutive rinsing of a sample with acetone, then 
methanol, then IPA for 5-30 seconds with each solvent is called AMI (acetone, methanol, 
IPA), which will be used throughout the rest of this thesis for brevity. The order in which 
the solvents are used and the use of pure solvents for each step is unique to this process. 
For instance, using equal parts of each solvent mixed together will not have the same effect.   
After AMI, additional cleaning of the side to be patterned is recommended for best 
results, especially for step A4 in Figure 2.13. Due to the ease of processing multiple wafers 
at once, a standard 30 second O2 plasma etch in the Vision RIE with the side to be processed 
placed up was used most often (parameters shown in Table A.1). Alternatively, a piranha 
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etch was found to be as effective. The CMOS wet bench piranha etch can process multiple 
wafers at once but requires 1-2 hours for the entire process. An alternative is to make a 
small volume bath in a glass dish (ensure the dish is not contaminated or shared use). The 
IEN facilities at GT set a limit that the ratio is to be 3:1 H2SO4:H2O2 (96% H2SO4 and 60% 
H2O2). The sulfuric acid should be added to the dish prior to adding hydrogen 
peroxide, and all proper PPE should always be worn. Consult staff members and do 
not carry this step out until given clearance by qualified personnel. After mixing the 
two chemicals a small amount of vapor will be released that will subside within ~30 
seconds at which point the wafer can be placed in the bath for 10 minutes with the patterned 
side up. After the bath is complete, rinse the wafer in H2O and follow the drying procedure 
above. Allow the piranha bath to come to room temperature before disposal and follow all 
necessary safety precautions during use. Note, piranha aggressively etches a wide range of 
materials and is not compatible with metals or photoresists, so this cleaning procedure is 
not recommended as a general clean procedure but can be used to intentionally remove 
deposited titanium, aluminum,  Al2O3, and in some cases SU-8 (underdeveloped or 
underexposed SU-8).  
After cleaning the wafer, 2 mL of SPR 220 was pipetted onto the pattern side and 
spincoated with a two-step process (Table A.6). The first step was 500 RPM for 5 seconds 
with a 1 second ramp up and the second step was 2500 RMP for 40 seconds with a 2 second 
ramp up, which produced films with ~7 μm thickness. For SPR 220 only a “soft” bake at 
110 °C on a hotplate for 3 minutes before exposure is required, post exposure bakes (PEB) 
caused the lithography to fail even though the datasheet recommends them. Any bubbles 
or imperfections resulted in pinhole defects during etching, so if the areas affected could 
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be covered with Kapton tape before etching then the process could proceed. If the 
imperfections are abundant or overlapping critical features, the SPR 220 was removed by 
soaking in acetone for ~5 minutes prior to an AMI clean and repeated SPR 220 spincoating.  
 Both manual lithography (Karl Suss Mask Aligner) and laser mask-writing 
(Heidelberg MLA150) exposure were explored for the SPR 220 lithography step that 
worked equally well. Using the manual Karl Suss mask aligner system, the film was 
exposed to 500 mJ/cm2 at 405 nm. For process A2, the alignment marks were oriented with 
the horizontal pattern on the left side of the wafer and the vertical pattern on the right side. 
For process B2, the alignment marks were flipped. This ensured that when the wafers were 
positioned for bonding in later processes that all critical features aligned. The hard mask 
designs for DSP were symmetric except for the alignment marks. During mask production 
the entire patterns were shifted due to the asymmetric alignment mark design so care was 
taken to reverse the orientation of one of the exposures. For these reasons, the Heidelberg 
was the preferred method of exposure. 
 The Heidelberg MLA150 is a maskless aligner that uses a 375 or 405 nm 
wavelength laser to write a digital mask directly onto a substrate. The advantage of this 
instrument is that no hard masks are required and, more importantly, the digital mask 
design comes with alignment marks that allow auto-alignment with ultra-high precision 
with the automated software, alleviating a source of human error during manual alignment. 
The symmetric mask design was centered on each wafer using the Heidelberg approach, 
which drastically improved the final device alignment and enabled easy wafer alignment 
in step C1. For the SPR 220, the pattern was written on the “fast setting” for 650 mJ/cm2. 
Note that for both the Karl Suss system and the Heidelberg system, overexposure is 
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acceptable for SPR 220. Aiming for higher dosages will result in slightly larger features, 
but also ensures that the films will develop without residue left behind.  
 After exposure, the wafers were held for 5-10 minutes at ambient conditions and 
then were developed in MF-319 at room temperature for 2-3 minutes, rinsed in H2O, and 
dried off with N2. Consistently agitating the bath by hand for the entire development 
process helped to keep the bath homogenized and developer rates constant. Visual 
inspection of critical features was carried out on an optical microscope, any residual SPR 
220 was removed by developing for another 15 seconds. A final oxygen descum (Table 
A.1) was carried out for 30 seconds to remove any remaining SPR 220. Before etching 
masks in steps A3 and A4, the wafers were baked in an oven at 100 °C for 15 minutes. 
Before step A4, the sample was baked at 100 °C in an oven for 12-24 hours. Before moving 
onto etch steps, especially when using manual alignment via Karl Suss, final wafer 
alignment was checked on the IR microscope to make sure that the features on each device 
would align. More than a 2 mm offset at the wafer level resulted in fracture during bonding, 
so if the overall alignment was wrong the entire SPR 220 was stripped and adjustments to 
the initial mask offset were made. For instance, while using the hard masks designed and 
fabricated at the GT-IEN facilities, a 1.5 mm offset on the mask for step A2 was found to 
be necessary. It is important to note that when using the Heidelberg with symmetric mask 
design there was no need to offset designs.  
A.1.3 SiO2 Mask Etching (A3, B3) 
Reactive ion etching (RIE) and inductively coupled plasma (ICP) etching are both 
effective options for etching SiO2. Both approaches use a fluorocarbon gas plasma for 
etching SiO2 although the etch rates and feature side wall profiles differ. RIE uses CHF3 
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as a plasma precursor, and it is a near isotropic etch which makes it ideal for etching thin 
layers of SiO2. During longer etches, RIE will etch horizontally under the photoresist mask 
to increase the patterned feature size, causing the features that are ultimately etched with 
deep reactive ion etching (DRIE) to have slightly different dimensions than what was 
patterned in the photoresist. During the anisotropic ICP process, which uses C4F8 as the 
source for plasma, the ions are accelerated towards the surface with a strong electric field 
and therefore features etched into the SiO2 mask have more vertical walls with precise 
dimension control. Additionally, ICP is a much faster process for a single wafer, etching 
thermal oxide at 67 nm/min vs 200 nm/min for RIE based on the specific approaches used 
in the DSP fabrication workflow.  
Before any etch of the SiO2 masking layer (Figure 2.13 step A3 and  Figure 2.14 
step B3), all noticeable bubbles or defects in the bulk photoresist film were covered with 
Kapton tape. Without covering these defects, the mask would be etched, which caused the 
DRIE step to etch these areas. As a result, trough-hole defects in the final device caused 
device fracture or fluidic leaking. Care was taken to avoid any coverage of patterned 
features with Kapton tape by visually inspecting the features on an optical microscope 
before etching.  
The specific instrument available (Plasma ThermTM ICP) for ICP etching at Georgia 
Tech required that ~5 mm of photoresist be removed from the edge of the wafer with an 
acetone-soaked swap. This prevented the wafer from sticking to the wafer clamp, which 
would cause the sample to break. A significant draw back of the ICP approach was that 
part of the SiO2 layer was inadvertently removed around the wafer edge where photoresist 
was removed, which had to be covered with Kapton tape before later DRIE steps. The ICP 
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approach is significantly faster for a single sample, so for some prototypes it was used for 
rapid iterations of device design. For reference, the etch parameters for the ICP are shown 
in Table A.2.  
Up to four wafers could be etched simultaneously for increased output using the 
RIE approach, and the risk of breaking the wafer was nonexistent. These advantages alone 
made the Vision RIE the preferred method of etching SiO2. When multiple samples are 
placed inside the RIE, the etch rate becomes less uniform and slower for the features. For 
this reason, the etch was designed to “over-etch” such that all features were etched through. 
The etch parameters for the Vision RIE were the same for both single and multiple samples, 
which is shown in Table A.3. To ensure that the SiO2 layer is etched through (with either 
etch method used), the SiO2 features were checked on a NanoSpec
TM Reflectometer with 
the “SiO2 on Silicon” program. Fit parameters should be less than ~0.5 and the thickness 
should measure <10 Å.  
A.1.4 Bulk Silicon DRIE (A4, A5, C2) 
Deep Reactive Ion Etching (DRIE) is an anisotropic, inductively coupled plasma 
(ICP) based approach used for generating high aspect ratio features with utility for a range 
of materials, including silicon. The process alternates the deposition of a uniform 
passivation layer for masking generated from a C4F8 plasma and an anisotropic ICP etch 
step with an SF6 based plasma. During etching, the ICP system accelerates ions to the 
bottom of features for higher etch rates vertically than horizontally, resulting in near 
vertical walls and high aspect ratio. For the DSP process, DRIE is used for processing the 
counterbore capillary interface (Figure 2.13 steps A4, A5) and the conditioner channel 
(Figure 2.15 step C2). The specific instrument used for all DSP processing was the 
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STSTM ICP with the parameters shown in Table A.5. For this process, it was found that the 
position of the butterfly valve (Automatic Pressure Control, displayed as APC % setting in 
the control software) for maintaining chamber pressure was critical. The valve position was 
found to be best for stable plasma between 65-69%. To verify if the position is correct, the 
plasma was observed through the viewing windows to check that the plasma did not flicker 
except for between the etch and passivation step. If the plasma was flickering, the most 
likely cause was found to be the APR position. Adjusting the valve position in 1% 
increments either up or down until the plasma was steady was found to be the most effective 
method for stabilizing the process.   
For all DRIE steps a “carrier wafer” was used for processing. The process wafer 
was mounted on a 500 μm thick Si carrier wafer with at least 1 μm of SiO2 on top. This 
carrier wafer ensured that if the DRIE process etched completely through the process 
wafer, the STS ICP chuck would not experience any damage. Traditionally, a type of 
Silicone based “cool-grease” is used to mount process wafers to carrier wafers, but this 
grease caused clogs in the final DSP device. Therefore, three pieces of Kapton tape were 
placed at equal angles around the edge of the wafer stack and wrapped from the top of the 
process wafer to the bottom of the carrier wafer. Using a razor blade, the pieces were 
trimmed to ~2 mm in length on the carrier wafer bottom side so that the tape covering the 
carrier wafer did not touch the chuck seal. On the top of the process wafer, small pieces of 
Kapton tape were used to cover the alignment marks so they did not get etched through 
during the processing. After covering all defects and alignment marks, and mounting the 
wafer, inspection of all features was carried out to make sure that no features were 
inadvertently covered/exposed.  
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The counterbore geometry used for capillary integration (inset, Figure 2.13) was 
achieved using a novel two-step masking process without backside alignment. Prior reports 
of this geometry required backside alignment and patterning, which was found to not be 
compatible with the DSP microfabrication workflow since patterning on the backside of 
the capillary interface wafer caused the wafers to delaminate after bonding in later steps. 
Prior to the first DRIE counterbore step in A4, the SPR layer patterned directly on 
top of the patterned SiO2 layer was baked in an oven set to 100 °C for at least 12 hours, 
with best results after a 24 hour bake. Note, baking can occur before or after mounting the 
wafer but the Kapton tape adhesive was more likely to leave a residue which was cleaned 
afterward when the entire mounted wafer was baked. Without baking, the photoresist can 
cause micromasking effects, which occurs when the SPR 220 is ablated from the surface 
and subsequently redeposited inside features. Increasing the O2 flow rate can help with 
these micromasking effects, but it also increases the bulk etch rate, reduces selectivity, and 
results in more isotropic etching. The wafer was then processed for a partial through etch 
by processing for 650 cycles with the parameters outlined in Table A.5. 
After etching, Kapton tape was removed and the wafer was soaked in acetone for 
10-20 minutes to remove bulk SPR 220. After, the wafer was place in a 3:1 piranha bath at 
room temperature for 60 minutes to remove all residual SPR 220 and passivation layers. 
The wafer was rinsed in H2O, then dried off and mounted on a carrier wafer as described 
above. The alignment marks were again covered with Kapton tape before the next 
counterbore DRIE step. For the final through etch, care was taken not to over-etch so the 
sample was etched for 325 cycles using the parameters in  Table A.5 to start. After 
completing the etch, the wafer was removed from the carrier wafer and a white LED was 
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placed behind the wafer to confirm whether the etch had gone through. If light was visible 
through all features, a backlit microscope was used to inspect the feature quality. If some 
features required additional etching while others were through, pieces of Kapton tape were 
placed over the finished features to prevent over etching effects and the wafer was etched 
for another 15 cycles until breakthrough was observed. 
After all features were completed, the device was sonicated for 15 minutes in 
separate baths of acetone, methanol, and then IPA. A small droplet of H2O was placed on 
a flat surface and the wafer was then pressed down on top of the droplet by hand to confirm 
that through flow was observed. At this stage, the wafer was cleaned in a piranha bath at 
120 °C for 30 minutes and rinsed in H2O to remove all residue from inside the counterbore 
interfaces.  
A.1.5 Membrane Metallization and Anodization (B4) 
After finishing the patterning of SiO2 on the process B wafer (Figure 2.14, step B3) 
an AMI clean process was carried out on both sides of the wafer followed by either a 
piranha clean or a batch O2 descum in the Vision RIE (Table A.1) with the unpatterned 
side placed up. Any defects or imperfections at this stage directly impacted the final device 
performance, so care was taken to ensure the side for metallization was free of defects.  
The metallization process developed by Tibavinsky et. al utilized a custom sample 
holder that increased the deposition rate and final thickness of evaporated materials in the 
CHATM E-Beam Evaporator tool.34, 43 The modified sample holder was attached to the 
standard 3 wafer holder by attaching clamps to the standard holder and suspending the 
custom holder by chain as shown in Figure A.1.43 The wafers were lowered from their 
standard height to a distance approximately 200 mm lower, which corresponded to 5 links 
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in the chain. A hole in the center of the custom sample holder allowed for the evaporated 
material to pass through for deposition rate monitoring via quartz crystalline microbalance. 
Although the monitored deposition rates and final thickness did not represent the actual 
deposition rates, by monitoring the measured values each deposited film was similar.  
The metallization was done in three steps. First, an adhesion layer of Ti was 
deposited by programming 250 Å at 1 Å/s followed by two steps of bulk Al deposited for 
12,500 Å at 5 Å/s. Between each step the instrument was given time to cool down so the 
crucibles did not break by holding for 15 minutes. The final thickness of the stack was not 
completely uniform, so when mounting the wafers the flats were placed facing the inner 
cut out so the thickness varied from the bottom to the top of the wafer. The final thickness 
was approximately 4 μm at the top of the wafer and 7 μm at the bottom. Note that at this 
Figure A.1: Custom mounting setup for increased deposition rate and final metal 
thickness in the CHA E-Beam. Adapted, with permission, from Tibavinsky, I.A., 
A microfabricated rapid desalting device for integration with electrospraying tip. 
2014, Georgia Institute of Technology. 
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stage piranha cleans were not compatible with the sample as they etched the Ti and Al 
layers. If the aluminum films appeared highly dull/non-reflective or had bulk defects, a 
piranha etch was used to remove the Ti and Al layers. This piranha etch was carried out in 
a separate bath due to the incompatibility with the CMOS wet-bench processes, and all 
waste from the bath was placed in a secondary container after cooling to room temperature.  
After deposition, the samples were anodized to produce a uniform, nanoporous 
alumina (Al2O3) membrane. Depending on the type of electrolyte used and the voltage 
applied, pore size can be controlled from 5 to 500+ nm in diameter.44, 82, 84-86 For the 
prototype DSP, oxalic acid was used as the electrolyte to produce 50 nm pores. A 
continuously stirred 4 liter bath of 0.1 M oxalic acid maintained at 0 °C in a chilled jacketed 
beaker was used for the anodization process. The cathode was the wafer itself, held by the 
positive lead alligator clip of the power supply, and the anode was a 30 cm graphite rod 
with carbon tape used to attach the ground lead of the power supply. Once the bath was at 
temperature, the wafer was placed in 1.5% chromic acid and 5% phosphoric acid at 65°C 
for 30 minutes to remove the native oxide layer. The wafer was rinsed in DI H2O and 
secured to the alligator clip and lowered into the oxalic acid bath such that all the 
conditioner channels patterned on the far side were submerged. A 40 V potential was 
applied between the wafer and graphite rod, which was observed to produce a current of 
80 mA. The sample was anodized for 45 minutes before the power was shut off and the 
sample was rinsed with H2O before being placed in the 1.5% chromic acid and 5% 
phosphoric acid bath at 65 °C for 30 minutes to etch the thin layer of Al2O3. This step 
exposes the preferred nucleation steps for the through pore anodization process. The wafer 
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was removed from this bath, rinsed again in H2O, and placed back into the oxalic acid bath 
with the same 40V potential for approximately 8 hours.  
To confirm the end-point anodization, the current was monitored. Generally, the 
measured current decreased throughout the anodization process from 80 mA to 5 mA. The 
current value gradually reduced until it reached a steady state level, at which point it was 
left to anodize for at least another hour to confirm the current does not change. If the wafer 
was removed before the anodization was completed, DSP mass exchanger device is not 
functional because if the pores do not penetrate the entire film thickness, the sample 
channel and conditioner channel are fluidically decoupled. If the device is “over-anodized” 
it can lead to delamination and bulk Al2O3 etching but was only observed after 15+ hour 
long anodization steps. After anodization was completed, the wafer was rinsed in H2O and 
then AMI. The integrity of the pore structure was confirmed using an SEM, as shown in 
the inset of Figure 2.14.  
A.1.6 SU-8 Lithography (B5) 
SU-8 is a biocompatible, negative type photoresist which is used to define the side 
walls of the DSP sample channel and to serve as the adhesive for sealing the final device.87-
92 This processing step is critical in the DSP fabrication process and required extensive 
optimization. Importantly, steps B5 and C1 (SU-8 lithography and bonding respectively) 
should be carried out within ~30 minutes of each other for optimal bonding performance.  
The anodized wafer was cleaned with AMI and then descammed for 30 seconds 
using the parameters outlined in Table A.1. Before beginning spincoating, the ambient 
temperature and humidity were recorded. Note that if the humidity is below 25% or above 
40% during SU-8 processing, the bonding process will fail (humidity values may measure 
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low near hot plates). The wafer was placed anodized side up in a spincoating instrument 
and ~3 mL of SU-8 3005 was poured directly on the wafer from the bottle. A 3 step spin 
process was carried out with the parameters in Table A.8. The first step was 500 RMP, 1 
second ramp, 5 second hold, the second was 3000 RPM, 2 second ramp, 40 second hold, 
and finally 4500 RPM, 0.5 second ramp, 3 second hold. The final high spin rate step was 
used to reduce edge bead, which will affect final bonding performance. Immediately after 
spincoating, the wafer was soft baked at 95 °C on a hotplate for 2 minutes and 30 seconds 
before backside alignment and exposure (no hold times or delays can occur from spin 
coating to exposure).   
Two alignment/exposure procedures, the manual EVG 620 backside aligner and the 
Heidelberg MLA150 maskless aligner, were explored for DSP fabrication that both worked 
effectively, although the Heidelberg MLA150 approach was far more repeatable. Using the 
EVG, the SU-8 layer was exposed to 195 mJ/cm2 dosage at 365 nm. The measured light 
intensity used to calculate exposure time was not adjusted, i.e., without the mask 
absorptivity taken into account. For hard mask exposure, a soda-lime masking material is 
recommended because it filters out high wavelength UV light that causes lateral cross-
linking under darkfield patterns in the mask. After exposure, the sample was immediately 
post exposure baked at 95 °C for 2 minutes and 30 seconds before holding for 10 minutes.  
For Heidelberg MLA150 exposure, the same spincoating and soft bake procedure 
was carried out before loading the sample for backside alignment. The optimal exposure 
dosage was 760 mJ/cm2 on the Heidelberg in “high quality” mode. This dosage differs 
drastically from the mask aligner dosage because the wavelength is 375 nm for the 
maskless aligner vs 365 nm for the EVG. After exposure, the sample was soft baked on a 
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hotplate at 95 °C for 2 minutes and 30 seconds. The sample was not held between exposure 
and development for the Heidelberg approach. 
Development was the same for both exposure processes. Prior to development the 
wafer was rinsed with DI H2O for 20 seconds to aid in the reabsorption of water into the 
film. The sample was then developed with agitation in SU-8 developer (MicroChemTM) for 
90 seconds, followed immediately but rinsing with IPA for 30 seconds. After IPA rinse the 
sample was again developed for 30 seconds in SU-8 developer before another 30 second 
IPA rinse, followed by a 15 second rinse in DI H2O and, finally, a 15 second rinse in IPA. 
Note that SU-8 is not compatible with acetone, so AMI rinses are not recommended. 
Additionally, for the rest of the processes the wafer carrier was covered in aluminum foil 
when not in yellow-light environments to avoid exposure to any broad spectrum light, 
which can overexpose the SU-8 layer and cause bonding to fail.  
A.1.7 Wafer Alignment & Bonding (C1) 
Since it relies so heavily on the SU-8 processing. aligning and bonding the wafers 
in DSP fabrication were also the processing steps that required extensive optimization. It 
was found that if the SU-8 was deposited on the capillary inlet wafer (separate prototype 
workflow, not presented here) bonding failed. It is hypothesized this is because the rough 
Al2O3 surface did not bond effectively to the smooth SU-8 surface. When the SU-8 was 
spun on the Al2O3 surface, the SU-8 penetrated into the porous surface and the smooth top 
surface of the spincoated SU-8 bonded well to the polished surface of the capillary interface 
wafer. 
Alignment of the wafers was carried out using an infrared (IR) microscope. As 
discussed, IR transmissibility was a critical material property for the stock Si wafers used 
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for DSP fabrication for this reason. Before alignment, both wafers were cleaned in the 
appropriate manner; for the process A wafer, full AMI and piranha cleaning or O2 descum 
was used and for the process B wafer a simple IPA rinse was used since SU-8 is sensitive 
to most cleaning processes. The process B wafer was prepared for bonding by placing three 
~8 mm pieces of Kapton tape on the conditioner channel side and then inverting the sample 
such that the adhesive side of the tape and the nanoporous membrane were facing up. In 
this orientation, the wafer was placed onto the IR microscope plate and the process A wafer 
was placed on top for alignment. With the backlight on the lowest setting, the IR sensitive 
microscope allowed for easy viewing of the patterned SU-8 features and all alignment 
marks through the Si layers. The wafers were first aligned using large alignment marks, at 
which point a single piece of the tape was folded over to secure the stack. The alignment 
could then be adjusted using a disparate feature, such as an alignment mark or an inlet hole. 
Once alignment was confirmed the final two pieces of tape were folded to secure the wafer. 
The entire stack was carefully lifted and 5 additional pieces of tape were added around the 
circumference of the wafer such that all 8 had approximately equal spacing. The alignment 
was double checked on the IR microscope before bonding.  
Bonding was carried out using the Obducat Nanoimprinter. The entire wafer stack 
was placed in the 4” wafer chuck with the inlet/outlet holes up and a sheet of polycarbonate 
was placed on top of the chuck before the o-ring holder was placed to secure the stack. The 
bonding program consisted of two steps. In the first step, pressure was set to 10 bar and 
temperature to 25 °C for 60 seconds and in the second step pressure was maintained at 10 
bar and temperature was increased to 130 °C for 30 minutes. The measured pressure 
increased to ~12.5 bar during this process due to thermal expansion effects. After bonding, 
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the polycarbonate sheet should be completely transparent and free of polymer residue. The 
presence of an opaque film indicates that the SU-8 was not cross-linked completely, and 
the final device would either delaminate or clog due to SU-8 reflow. Under-exposed SU-8 
will reflow and clog the final DSP devices, while over-exposed SU-8 will not bond. After 
bonding, the wafer stack was checked on the IR microscope to ensure none of the internal 
channels had clogged or changed in dimension.  
A.1.8 Membrane Release (C2) 
Membrane release is comprised of three main steps. First, the bulk Si is removed 
with a DRIE process, then the SiO2 and Ti layers are removed with a C4F8 RIE, and finally 
the barrier layer of Al and pores are opened with a CF4 RIE step. The DRIE process is 
carried out after bonding is completed. The wafer stack was mounted to a carrier wafer 
with tape to protect the capillary interface surface. Once again the alignment marks were 
covered with Kapton tape, and the DRIE process was run for 475 cycles with the 
parameters in Table A.5. If bulk silicon was left on the bottom of the conditioner channel, 
an additional 50 cycles were added until all the conditioner channels appeared to have a 
reflective finish due to the SiO2, Ti, Al2O3 layers underneath. Bubbles in the SiO2 surface 
indicate poor bonding, which can be attributed to localized defects or over-exposed SU-8.  
After the DRIE step was completed, the bonded wafer was removed from the carrier 
wafer and transferred to the Vision RIE for a 3 hour etch according to the parameters in 
Table A.3. After the etch, the sample channels were visible through the remaining layers 
of Al and Al2O3 and the bulk of the membrane appeared dull; the presence of a reflective 
layer or the inability to make out the sample channel indicated an incomplete SiO2 etch. 
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The final etch step was used to remove the barrier layer from the anodization 
process. Multiple options were explored, including the wet etch utilized by Tibavinsky, but 
the most effective and repeatable method was a CF4 RIE etch. This step was found to be 
the least repeatable of the entire fabrication process, which is likely due to a non-uniform 
Al2O3 layer. For this reason, the devices were diced prior to the final CF4 etch release of 
the membrane. Over etching the membrane in this step resulted in bulk leaks and device 
failure, while under-etching prevented efficient transfer between the sample and 
conditioner channels.  The etch was carried out on the UnaxisTM RIE with the parameters 
in Table A.4. For most devices, the optimal etch time was found to be 13 minutes and 45 
seconds, but bulk defects were observed with as little as 10 minutes and some devices were 
found to require 20 minutes of etching before performing well.  
A.1.9 Dicing  
Dicing was carried out on an ADTTM 7100 dicing saw. The wafer was mounted on 
the tape with the conditioner channel facing up. To protect the membrane, Kapton tape was 
placed over each conditioner channel to prevent the high flow-rate H2O, used for keeping 
the blade cooled, from depositing debris or fracturing the membrane. Dicing was found to 
be successful independent of blade type, although a nickel type blade with a 100 μm 
thickness was used predominantly. After dicing, each device was removed and the tape 
was carefully removed.  
A.1.10 Inlet & Outlet Capillary Integration (C3) 
A DymaxTM PC-3D light welder with the included photo-sensitive epoxy were used 
to glue the inlet/outlet capillaries into the counterbores of the bonded mass exchanger 
 133 
device. A 360 μm OD capillary was placed tangent to the SiO2 surface and slid gently into 
the counterbore opening. Once the capillary was self-supporting, epoxy was dispensed 
around the entire capillary interface and immediately exposed to the UV source for 20 
seconds for complete cross-linking. For the inlet, a 360 μm OD 50 μm ID PEEK tube from 
Upchurch ScientificTM was used, while the outlet was an ESI capillary, generally a 30 μm 
tapered fused silica emitter from NewObjectiveTM.  
A.2 RIE, ICP, and DRIE Parameters 
The Vision RIE (renamed the CTRL Layer RIE) was used for descum (Table A.1) and 
SiO2 etching (Table A.3).  
Table A.1. Vision RIE O2 descum/clean parameters 
Pressure 60 mTorr 
Power 150 W 
Temperature 25 º C 
O2 50 sccm 
Time 15-60s 
The Plasma ThermTM ICP was an alternative to the Vision RIE. The standard SiO2 etch 
parameters are shown in Table A.2 
Table A.2. Plasma Therm ICP Etch Parameters 
Pressure 5 mTorr 
Ar flow rate 5 sccm 
C4F8 flow rate 15 sccm 
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CO2 flow rate 28 sccm 
ICP power 800 W 
Chuck power 40 W 
Time 45 min 
The Vision RIE was the preferred method for etching masking layers of SiO2 and the layer 
of SiO2 on the backside of the membrane, the etch parameters are shown in Table A.3.  
Table A.3. Vision RIE Parameters 
Pressure 40 mTorr 
CHF3 flow rate 45 sccm 
O2 flow rate 5 sccm 
Power 250 W 
Time 0-3 hours 
 
The UnaxisTM RIE was used for CF4 etching of the membrane for pore opening. The 
parameters are shown in Table A.4. 
Table A.4. Unaxis RIE Etch Parameters 
Pressure 100 mTorr 
Power 250 W 
CF4 18 sccm 
O2 8 sccm 
Time 10-20 min 
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The STS ICP was used for etching bulk features in Si. The parameters are shown in Table 
A.5 
Table A.5. STS ICP Bosch (DRIE) Parameters 
 Passivation Etch 
SF6 flow rate 0 130 sccm 
C4F8 flow rate 85 sccm 0 
O2 0 sccm 13 sccm 
Coil Power 800 W 800 W 
Platen Power 0 W 10 W 
Pressure 0.1 mTorr 0.1 mTorr 
Time 9 s 11 s 
 
A.3 SPR 220 Spincoat and Exposure Parameters 
SPR 220 is a positive type photoresist used for masking purposes in process A (Error! R
eference source not found.) and process B (Error! Reference source not found.). 
Table A.6: SPR 220 Spincoat Parameters 
Step RPM Ramp (s) Hold (s) 
1 500 1 5  
2 2500 1 40 
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Soft Bake 3 min @ 110 °C 
 
Table A.7: SPR 220 Exposure and Post Exposure Bake (PEB) Parameters 
Instrument Dosage PEB 
Karl Suss 500 mJ/cm2 @ 405 nm Not required; 




650 mJ/cm2 @ 405 
nm, fast setting OK 
 
A.4 SU-8 3005 Spincoat and Exposure Parameters 
SU-8 3005 is a negative type photoresist with excellent biocompatibility used to define the 
sidewalls of the DSP sample channel and to serve as an adhesive layer for bonding.  
Table A.8: SU-8 3005 Spincoat parameters 
Step RPM Ramp (s) Time (s) 
1 500 1 5  
2 3000 2 40 
3 4500 0.5 3 
Soft Bake 2 min 30 s @ 95 °C 
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Table A.9: SU-8 3005 Exposure and Post Exposure Bake (PEB) Parameters 
Instrument Dosage PEB 
EVG 620 195 mJ/cm2 @ 365 nm Bake @ 95 °C 
2 min 30s ; 




760 mJ/cm2 @ 405 






FLUIDIC INTERFACE PACKAGE PRODUCTION 
The fluidic interface package design had two iterations: one for counterflow used in early 
experiments and one for crossflow used in later experiments. Although the notes in the 
drawings indicate polycarbonate stock material for the machined top, PEEK was also used. 
PEEK is not transparent and therefore care should be taken to monitor bubble formation in 
the conditioner channel. The bottom portion of the DSP fluidic package was machined out 
of PEEK. The gasket was laser machined by generating a .DXF trace of the groove in the 
package drawings. Different offsets from the inner to outer traces were used depending on 
the laser power (multiple lasers used). The final width of the gasket should be less than 0.5 
mm to fit into the machined recess.  
 
Figure 0.1: Production drawing for counterflow fluidic interface top. 
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Figure 0.2: Production drawing for crossflow fluidic interface top. 
Figure 0.3: Production drawing for bottom of fluidic package. 
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ION TRANSFER INTERFACE DRAWINGS 
The production drawings for the ion transfer interface used for the Q-Exactive Plus are 
shown in this appendix. The polycarbonate pieces the gasket, and the spacer are assembled 
to form the box assembly. The bushing bar assembly was attached to the MS box with hand 
tightened fasteners before fixed on the front of the MS to ensure proper fit. The MS side 
supports have build in compliance in the form of slotted holes for all fittings. The left side 
support shaft has a small recess to allow for the ball detent safety override. 
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Figure 0.1: Gasket used to seal ion transfer box to the front of the MS system. 
Figure 0.2: MS side of the ion transfer box; gasket designed to fit into recess. 
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Figure 0.3: Bottom of ion transfer box, for interfacing with vacuum system. 
Figure 0.4: Front of ion transfer box, where ions enter system. 
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Figure 0.5: Right hand side of the ion transfer box. 
Figure 0.6: Top of the ion transfer box. 
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Figure 0.7: Left hand side of the ion transfer box. 
Figure 0.8: Spacer used to attach to left/right hand side of ion transfer box to 
support a commercially available latch which spanned from spacers to catch plates, 
where the latch catch was fixed.  
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Figure 0.9: Bushing housing, for pressfit of plastic bushing. Two of these parts 
attach to the bearing cross bar. 
Figure 0.10: Bushing cross bar, used to allow for adjustments of the mounting 
interface after installation. 
 146 
Figure 0.11: Catch plate used to mount latch catch to MS supports. 
Figure 0.12: Side plate used to attach to vertical shafts and to support catch plate 
with build in adjustment capability in the form of slotted holes. 
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Figure 0.13: Shaft used to support ion transfer box on MS side. This shaft functions 
in slot without safety override ball detent. 
Figure 0.14: This modified version of the shaft is used to allow room for the ball 
detent safety override in the QE plus model. 
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